Arachnoiditis: leveraging crowdsourcing and AI in a cross-sectional study of 1,105 cases to improve identification, understanding, and treatment

Lori Verton[1], Noga Minsky[2,3], Eran Dotan[2,4], Roni Sharon[2,5], Megan Black[1], Patricia Gomes[1], Deepmala Rana Bhat[1,6], Shristi Sharma[1,6], Ishna Singh[1] and Linda Bavisotto[1*]

[1] Arachnoiditis and Chronic Meningitis Collaborative Research Network (ACMCRN), London, Ontario, Canada

[2] Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

[3] Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel

[4] StuffThatWorks Ltd, Tel Aviv, Israel

[5] Department of Neurology, Sheba Medical Center, Ramat Gan, Israel

[6] Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada

*Correspondence:

Linda Bavisotto

bavisotto@acmcrn.org

Abstract

Background

Arachnoiditis, a painful and potentially disabling neurological condition, results from persistent inflammation of the spinal cord pia-arachnoid membranes following injury. While considered rare, the condition is underdiagnosed. Research on symptomatology, diagnosis, and treatments is scarce, hindering clinical management. Artificial intelligence (AI) offers promising opportunities for rare diseases, enabling large-scale pattern identification. This study used traditional research methods coupled with AI technology to characterize patient-reported clinical presentation, comorbidities, aggravating factors, and treatments for arachnoiditis.

Methods

This retrospective cross-sectional study utilized data from StuffThatWorks (STW), an online crowdsourcing platform for people with chronic diseases. Multiple choice and free text responses were assessed both quantitatively and qualitatively. Novel AI/machine learning algorithms were used to further analyze the data, including the STW cross-condition score (higher scores more indicative of arachnoiditis) and the STW treatment efficacy model generating effectiveness and detriment estimates, with binomial proportion 90% confidence intervals.

Results

Of 1250 international participants, 1105 reporting a physician-confirmed diagnosis were included. Participants were predominantly USA-based (71.4%), female (75.9%) and ≥46 years

old (73.1%). Of 712 symptoms grouped into eight categories, eighteen were more indicative of

arachnoiditis (by cross-condition score). The most frequent symptoms were lower back pain

(43.5%), leg pain (41.6%) and back pain (39.1%). Prolonged sitting (62.5%) and prolonged

standing (58.3%) were the most common aggravating factors. Comorbidities were led by

degenerative disc disease (32.3%), spinal stenosis (25.3%) and fibromyalgia (25.0%). The most

frequently used treatments were gabapentin (37.9%), physiotherapy (30.1%) and pregabalin

(26.5%). Treatments with the highest patient-rated effectiveness (by STW model, 90% CI) were

low-dose naltrexone (28.1%, CI 20.0-37.0), ketamine infusion (24.8%, CI 16.9-33.4) and

fentanyl (21.1%, CI 14.7-28.1). Epidural corticosteroid injections showed the highest detriment

(38.5%, CI 28.0-45.9).

Conclusion

As the largest observational study of arachnoiditis to date, made possible with novel

methodological approaches, this work offers new insights with potential to improve diagnosis

and management.

Keywords

Arachnoiditis, Artificial intelligence, Chronic meningitis, Spinal diseases, Leptomeninges,

Neuroinflammation, Chronic pain, Patient-reported outcomes, Radiculopathy, Rare diseases

Background

Arachnoiditis is a painful, potentially debilitating neurological condition resulting from persistent inflammation of the spinal cord pia-arachnoid membranes (leptomeninges) and the subarachnoid space between them [1–3]. A cascade of neuroinflammation in response to injury—a normally healthy mechanism, but persistent or excessive in arachnoiditis—results in early spinal nerve swelling and leads to thickening and clumping of spinal nerve roots [1,3,4]. The process can be focal or diffuse, and over time becomes compounded by the development of permanent scarring and adhesions, entrapping nerves and disrupting the normal flow of cerebrospinal fluid (CSF) in the subarachnoid space. Fibrosis and CSF flow disturbances can lead to spinal cord tethering, syrinx formation, myelomalacia, spinal cord atrophy, and myelopathic symptoms [1,2,5–9].

Arachnoiditis manifests with a wide spectrum of clinical presentations, and the course of the condition is highly variable [10]. Advanced stage adhesive arachnoiditis is commonly characterized by intractable neuropathic pain, significant mobility issues and myriad neurologic impairments [1,9,11]. Complications can extend to the genitourinary, gastrointestinal and autonomic nervous systems [12,13]. Together, these disease expressions can lead to significant morbidity, disability and shortened lifespan [3,13,14]. Considered a rare condition, but often misdiagnosed and overlooked, much remains unknown about the epidemiology and natural history of arachnoiditis, or the efficacy of interventions [1,15].

Clinical symptoms of arachnoiditis can appear acutely within hours or days of an inciting event, or develop gradually over months to years, or even decades, often leading to delayed diagnosis or misdiagnosis [1,9,11,16]. The condition may be triggered by a variety of

factors, primarily involving physical damage or chemical injury to the spinal cord, or by

infection of the spinal meninges. Injury may occur because of trauma to the spinal cord,

subarachnoid hemorrhage or other introduction of blood into the CSF, edema, or post-surgical

or post-procedural inflammation [1,5,17,18]. Exposure of the meninges and CSF to a variety of

chemicals has also been documented to cause arachnoiditis, with offending agents including

intrathecal chemotherapy, corticosteroids, oil-based radiographic contrast agents, detergent

solvents, contaminants, and preservatives such as polyethylene glycol, to name just a few

[1,19]. Infectious meningitis can be caused by fungal, bacterial, viral, or parasitic pathogens

[1,20]. Chronic meningitis, or aseptic arachnoiditis, are terms sometimes used to refer to

inflammation without evidence for a causal infectious pathogen. The condition can also be

triggered by autoimmunity, for example as an adverse immune event due to immune

checkpoint inhibitor therapy of various malignancies [21]. In addition, idiopathic cases are not

uncommon [1,22].

Whereas arachnoiditis arising as a late complication of meningeal infection may favor

cervical and thoracic spine distribution [1], where the disease tends to be more progressive [2],

the current predominance of lumbar arachnoiditis appears to be related to an increasing

frequency of invasive lumbar spinal interventions, including various surgical techniques as

well as epidural anesthesia and injections. Iodinated oil-based myelographic contrast imaging

agents, such as iophendylate, administered via lumbar puncture into the subarachnoid space,

have been associated with the development of numerous cases of iatrogenic arachnoiditis

[1,4,14,19], and these agents were subsequently removed from the market. Fungal meningitis

and arachnoiditis were documented in a number of clustered cases arising from

contamination of methylprednisolone in epidural injections in 2012 [23–25] and of spinal

anesthesia in 2023 [26]. An updated American practice advisory was issued in 2017 on the

prevention, diagnosis and management of infectious complications associated with neuraxial

techniques [27].

It is important to emphasize that most individuals with the aforementioned exposures

do not develop arachnoiditis. Some individuals may have underlying risk factors that

predispose them. There appears to be an association with pre-existing anatomic spinal

abnormalities as well as age-related degeneration, particularly in lumbar arachnoiditis

[3,7,14,28,29]. These conditions in turn also lead to increased invasive spinal interventions,

with multiple spinal interventions (of any kind) or traumatic procedures being more closely

associated with the development of arachnoiditis [1,4,30]. There may be an increased risk in

persons with auto-immune or systemic inflammatory conditions, such as autoimmune

vasculitis, ankylosing spondylitis, mixed connective tissue disease or rheumatoid arthritis

[1,31–33]. Additionally, a potential association with genetic connective tissue disorders, such

as Ehlers-Danlos Syndrome (EDS), has been described in a limited number of studies [34,35].

Rare cases of familial arachnoiditis with syringomyelia have been documented [36], suggesting

the possibility of an unidentified genetic susceptibility component in these individuals. A

potential association between arachnoiditis and Tarlov (perineural) cysts has also been

reported [34,37,38]. Various authors suggest that, in many cases, arachnoiditis is likely to

result from a combination of risk factors or inciting events [4,14,34,39].

Diagnosis of arachnoiditis is based on individual history, clinical findings and MRI

features. MRI is the preferred imaging modality, although CT myelography may be used when

MRI is contraindicated [29]. Over the past 50 years, several staging classification systems for

arachnoiditis have been proposed and modified based on symptoms, histopathology,

morphology and patterns of radiographic progression [14,40,41]. Expanding upon the

pathognomonic radiological patterns first established in the 1980s [40,42], recent diagnostic

studies of advanced stage adhesive arachnoiditis show that MRI findings may include

abnormal clumping and irregular distribution of spinal nerve roots, abnormal nerve root

contours, nerve root enhancement, synechia, loculated and typically dorsal arachnoid cysts,

as well as signs of CSF flow disturbance [10,28,29,43]. While radiological staging

classifications have focused primarily on lumbar arachnoiditis, disease occurring in other

spinal areas and the brain may be even more difficult to characterize on MRI [44–46].

Several limitations complicate the diagnosis of arachnoiditis in clinical practice.

Imaging findings are highly variable [29], and correlate poorly with symptom severity [43,47]. In

the cervicothoracic spine, neurosurgical observations show that MRI often incompletely

visualizes the extent of chronic arachnoiditis, especially focal arachnoiditis [44,45]. In the

lumbar spine, endoscopic surgery suggests that, in some cases, MRI may fail to identify the

condition at all [37,48,49], leading some authors to propose that mild arachnoiditis may be

overlooked in patients with unexplained lumbar radiculopathy symptoms but normal MRI

studies [50]. Adding to these diagnostic challenges, acute iatrogenic lumbar arachnoiditis may

initially present with minimal MRI findings – early imaging may show only nerve root

enhancement before other characteristic features develop, or may appear entirely normal [51–

55].

To address these limitations, several diagnostic methods have recently been described.

In the cervicothoracic spine, specialized MRI sequences and morphometric analyses for

improving visualization or inferring diagnosis have been employed [44,56–59]. In the lumbar

spine, proposed approaches include prone MRI to detect failure of the nerve roots to migrate

ventrally with gravity due to nerve root tethering [60], and morphometric analysis to assess for

mildly enlarged thecal sac dimensions [22,48,61,62]. MR neurography of the lumbosacral

plexus has also detected arachnoiditis not otherwise apparent on standard MRI [63]. In the

absence of a definitive diagnostic test and reflecting a lack of clear consensus in the field,

Epstein and Agulnick [47] have suggested that a characteristic constellation of symptoms

alone should suffice to make the clinical diagnosis of lumbar arachnoiditis, without the

requirement for radiographic confirmation.

Early and accurate diagnosis is important, as some therapeutic options for

arachnoiditis may be more effective when given in the initial stages of neuroinflammation.

When the diagnosis is not definitive, however, early intervention may be delayed to avoid

possible complications. In those with recent onset, early stage arachnoiditis, a variety of anti-

inflammatory, fibrinolytic, and immune-suppressive therapies have been empirically offered in

an attempt to arrest or slow the process of fibrosis and neuropathic progression

[1,12,53,64,65]. According to several recent reports, high-dose corticosteroids administered in

the earliest stages of acute arachnoiditis, often in iatrogenic cases, have led to recovery in the

short term [52,53,64,66,67]. However, the evidence is mixed, not all patients respond or

respond completely, and some patients recover spontaneously [1,52]. Most reports are

missing sufficient details. Further studies with standardized treatments and long-term

outcome assessments are needed as a critical research priority.

In patients experiencing progressive neurological deterioration, surgical intervention

such as detethering procedures, adhesiolysis, cyst fenestration, and decompression of

intradural arachnoid cyst or syrinx with or without shunting may be indicated

[1,2,5,44,62,68,69], however these procedures carry inherent risks of potential further

compromise in neurological function as well as development of post-operative inflammation

and scarring, which may lead to arachnoiditis recurrence. The primary surgical objectives are

to restore or improve CSF flow at sites of obstruction and to alleviate spinal cord compression.

The majority of contemporary literature on surgical management report on cases of

thoracic and cervical arachnoiditis, although some have included lumbosacral cases [5].

Favorable surgical outcomes have been reported, particularly early in disease prior to

significant spinal cord damage [2], although follow-up is often short and information

incomplete. There is relatively consistent evidence indicating that patients with focal spinal

involvement of arachnoiditis (limited to several vertebral segments) have better surgical and

neurologic outcomes post-operatively than those with extensive/diffuse spinal involvement

[2,44]. Minimally invasive neurosurgical approaches such as percutaneous intrathecal

endoscopy continue to evolve [37,48,49,62,70,71] and are sometimes combined with limited

laminectomy procedures [2,69] to allow direct visual assessment and safe removal of

adhesions in spinal segments adjacent to the laminectomy margins, extending the range of the

surgeon's reach beyond what would be possible with conventional laminectomy.

For patients who are not surgical candidates, management focuses on symptom-

directed supportive care and comprehensive chronic pain management [72,73]. Current

pharmacological and non-surgical interventions have variable results, typically providing

modest symptom relief at best, often with limited long-term benefit [1,3,11,12].

Substantial hurdles have impeded studies regarding the diagnosis, natural history and

treatments for arachnoiditis. One challenge is the lack of standardized terminology for

arachnoiditis across its varying degrees of severity, with Palackdharry et al. identifying up to 63

different terms used across specialties [1]. Determining clinically significant pathology also

remains unclear [74,75]. In addition, because arachnoiditis spans multiple specialties without

fitting neatly within one, research is fragmented [74]. Consequently, limited literature exists

regarding pathophysiology, symptomatology and accurate diagnosis, rendering correct

identification of the condition difficult. Inaccurate diagnosis may be common, as reflected by

poor inter-rater reliability (kappa score 0.05) in a 2021 study where five specialized radiologists

reviewed MRI images from 96 patients with hallmark criteria of the disease [28]. The

inconsistent lag times between insult and clinical presentation may further contribute to

delayed and missed diagnosis [10,61]. Chronicity of symptoms and the presence of

comorbidities may also complicate the clinical picture.

In recent years, the advancement of bio-registries, online patient advocacy groups,

digital health platforms, and disease registries, along with big data analytics, have begun to

overcome financial and logistical hurdles to understanding and treating rare diseases. In

addition, there has been increasing interest in arachnoiditis, with the number of publications

growing [1,76]. Following a collaborative research network model in which patient-led

initiatives have successfully accelerated research into rare diseases [77-78], the Arachnoiditis

and Chronic Meningitis Collaborative Research Network (ACMCRN) [79] advocated for the

establishment of an arachnoiditis research community on the digital health platform

StuffThatWorks (STW) [80]. The platform is structured to enable community-driven research

and insights. This study represents a retrospective analysis of the data accumulated through

this initiative in order to help advance understanding of the condition. It characterizes the

symptoms, aggravating factors, comorbidities and treatments among a large cohort of

individuals living with arachnoiditis. This work serves as a prelude to the creation of an

international arachnoiditis patient registry and the development of further studies.

Methods

Study design and data collection

This study is a retrospective cross-sectional analysis of observational patient-reported

data collected by STW [80]. STW is a free commercial crowdsourcing digital health platform

with approximately 2.9 million members across 1,261 medical conditions at the time of this

writing. It provides an online venue for people living with specific medical conditions to

voluntarily share structured information about their symptoms, treatments and outcomes

within condition-specific groups, termed "communities". This information is de-identified and

aggregated into community insights that form an accessible organized knowledge database,

enabling community members to self-educate. Natural language processing and machine

learning algorithms aggregate and analyze entries to generate insights about age of onset,

symptoms, aggravating factors and treatments. After several hundred responses are collected,

the algorithm ranks treatments according to effectiveness; with larger numbers of responses,

the model estimates the probability of treatment effectiveness based on user assessments.

Participation in the STW online survey platform is entirely voluntary, confidential and

anonymous, and participants retain the right to opt out of the platform and data sharing at any

time. Each of the STW chronic disease communities utilizes a common English-language,

structured medical questionnaire. This includes demographic items as well as aspects of

medical history, such as symptoms, diagnosis, treatments, aggravating factors, clinical

indicators, and comorbidities, along with assessments of quality of life and daily functioning.

With the exception of several mandatory questions, including current age and sex at birth,

participants are free to disclose only information they want to share.

For the purposes of the current retrospective study, survey data were accessed in

January 2023 and provided to the authors in aggregate format, with age categories, rather than

precise age. Compiled data comprised participant responses to a questionnaire, including

current age, sex at birth, age at symptom onset, symptoms, aggravating factors, comorbid

conditions, and all previously attempted arachnoiditis treatments (including medicines,

supplements, procedures, protocols, dietary changes, alternative or complementary

therapies, classes). Supplementary Material 1 lists the specific STW survey questions used in

the data analysis for this study. Many survey questions used open-text fields so as not to limit

responses to a predetermined list. This exploratory approach necessitated that compiled

results include both qualitative and quantitative data.

Participants

Participants were users of the STW platform who voluntarily joined the condition-

specific arachnoiditis community through multiple pathways, including organic discovery as

well as promotion by ACMCRN [79]. ACMCRN, a patient advocacy and research organization,

raised awareness of the arachnoiditis research community on the STW platform by drawing on

its existing networks through social media and word-of-mouth. ACMCRN had no financial

arrangement with STW and offered no incentives to participate on the STW platform. To be

included in the study analysis, participants had to indicate that their arachnoiditis was

diagnosed by a physician.

Data analysis

Responses to open-ended questions were coded into structured entities using STW's

proprietary "normalization tool" as a component of natural language processing. For example,

for a question regarding main symptoms, the answer "leg weakness and tingling" would be

normalized into two different "symptom" entities: "leg weakness" and "leg tingling". Numbers

for each response were given out of the total number of valid responses (n), after exclusion of

patients who did not answer the question and responses that were not normalized

successfully by the normalization tool.

Quantitative data are reported as frequencies and percentages. Quantitative results

also include values derived from an innovative algorithm unique to STW, the proprietary "STW

cross-condition score". This score uses AI-based models to measure how specific an entity or

response is to one disease community when compared to all other chronic disease

communities on the platform. The scale ranges from 1-10, with a score of 10 for an entity (such

as a symptom, aggravating factor or comorbidity) which is very commonly reported in one

community (e.g., arachnoiditis) but is rarely reported in others. Thus, higher scores indicate

higher specificity for the condition of interest. A cross-condition score ≥ 6 is highly indicative of

a given condition; a score between 3-5 is moderately indicative for the condition; and a score <

3 is a weak indicator for the condition. Novel research approaches are increasingly recognized

as important for advancing understanding of rare diseases [81]. Given that results from other

STW analytical models have demonstrated consistency with traditional research findings [82-

83], the authors included the cross-condition score data in addition to standard research

results.

To evaluate treatment effectiveness, alongside the primary data, a proprietary STW

treatment efficacy model was used [82-84]. Treatment effectiveness was expressed as an

estimated ratio of how many respondents rated a treatment as effective, out of the total

number of reports of this treatment (i.e. number of effective reports/numbers of tried reports),

while accounting for the level of certainty in the estimate based on the overall number of

reports for each treatment. A hierarchical Bayesian calculation generates a binomial

proportion confidence interval around the estimated proportion. To prevent overestimation of

the effectiveness of rarely used treatments, the model accounts for the number of reports on

each treatment, such that treatments with many reports are given greater weighting than those

with few reports. The model does not distinguish between treatments which were taken for

specific symptoms but rather assumes that all treatments are targeting the condition as a

whole. The output is expressed as a percentage together with a 90% confidence interval.

Where a large volume of findings was captured from open-ended questions, results are

presented according to a combination of both quantitative and qualitative methods.

Qualitative analysis utilized content analysis methodology and categorization [85] of like

responses for symptoms and aggravating factors, where ≥ 1% of the total study population

entered the same response. This analysis enabled a detailed exploration of the full breadth of

responses. In the absence of substantial prior research, qualitative methods are critical for

generating insight, and, in the context of rare diseases, mixed method approaches are valued

for incorporating lived experiences as meaningful input [86-87]. Although three authors (MB,

LB, IS) did the content analysis and categorization, all authors agreed upon the final

categorization of qualitative data.

The STW proprietary tools used in this study were applied within the platform

environment. Subsequent to the data extraction performed by STW, the aggregated outputs

generated by these models were shared with the authors, who have further analyzed and

interpreted them in this report. No modifications to the underlying algorithms were made for

the purposes of this study.

At the conclusion of the project, ACMCRN offered a summary of aggregate study

findings and insights to the arachnoiditis online support groups community in a series of

publicized online webinars. The sharing back of results to the participant community reflects

recognized ethical principles of reciprocity and respect for participants' contribution to the

research.

321   Ethics and data protection

Participation in the STW platform is voluntary, and the platform is designed to be

transparent to its users, including in its use of artificial intelligence. Individuals join to share

experiences related to specific health conditions and benefit from access to insights

generated from their aggregated community data. At registration, before sharing any data,

users agree to the platform's terms of use and privacy policy, which inform participants that

user-contributed information is handled in de-identified form and may be used for research

purposes, including secondary analysis by external researchers. The policies specify that any

data shared externally will be provided in aggregated form only. Participants may withdraw

from the platform and discontinue data sharing at any time, retaining ongoing control over their

contributed data. For any participants under the age of 16 years, a parent or guardian was

required to register and complete the questionnaire on their behalf.

STW obtained ethics approval from the Helsinki/IRB Committee of Sheba Medical

Center (Ramat Gan, Israel; protocol #7356-20-SMC) for the collection and analysis of de-

identified data for medical research across its chronic disease communities. This study

analyzed de-identified, routinely collected data from the STW digital health platform,

presented to the authors in aggregate form. Given that each participant had previously

consented at registration to the use of their de-identified data for research purposes, including

by external researchers, and that secondary analysis of existing data posed minimal risk of re-

identification—a key ethical consideration in digital health platform use [88]—the Sheba

Medical Center Ethics Committee approved a waiver of requirement for additional consent for

use of the medical questionnaire for research purposes. The present study falls within the

scope of this approval.

Data collected by STW are stored in a de-identified manner, with each user assigned a

non-indicative number. For the present study, data extraction and aggregation were performed

within the STW platform by one author (ED) who was affiliated with STW at the time the data

were accessed. The dataset provided to the remaining members of the research team

contained only aggregated information summarizing symptoms, treatments, aggravating

factors, and comorbidities at the population level. No individual-level data capable

of identifying or re-identifying participants were shared with the authors. This study therefore

represents secondary analysis of de-identified, aggregated user data. It was conducted in

accordance with the principles of the Declaration of Helsinki and consistent with recognized

ethical guidance for conducting health research with online communities [89].

Results

Demographics

Between July 2020 and December 2022, 1250 individuals enrolled on the STW platform

as members of the arachnoiditis research community. Of these, 1105 (88.4%) affirmed that

their diagnosis of arachnoiditis had been confirmed by a doctor, and only their data were

included in the study cohort for the following analyses.

Study participants were international, with the majority (71.4%) from the United States,

and three quarters (75.9%) were female. White or European ethnicities were predominant

among survey participants, while black or African American, Asian, and Hispanic ethnicities

were relatively underrepresented. Specific demographic characteristics of the study

participants are summarized in Table 1.

 Table 1. Demographic characteristics of 1105 study participants

Characteristic	n	%
Sex (at birth)		
Female	839	75.9
Male	266	24.1
Country		
United States	789	71.4
United Kingdom	77	7.0
Canada	50	4.5
Australia	31	2.8
Germany	12	1.1
South Africa	7	0.6
Others	139	12.6
Age at time of survey [a]		
0-18 years	3	0.3
19-30 years	43	3.9
31-45 years	252	22.8
46-65 years	615	55.7
66+ years	192	17.4
Age at time of symptom onset [b]		
0-18 years	26	2.5
19-30 years	133	13.0
31-45 years	389	38.1
46-65 years	408	39.9
66+ years	66	6.5
Ethnicity [c]		
White	943	89.0
European	207	19.5
American Indian or Alaska native	45	4.2
Hispanic or Latino	45	4.2
Asian	20	1.9
Black or African American	16	1.5
Arab or Middle East	9	0.8
Body Build [d]		
Significantly underweight	25	2.2
Moderately underweight	78	7.1
Average weight	441	39.9
Moderately overweight	452	40.9
Significantly overweight	109	9.9

n, number of participants in each category

[a] Percentages sum to 100.1% due to rounding

[b] Not all participants reported age at initial onset (n = 1022)

[c] Totals for ethnicity are greater than 1105, and percentages exceed 100%, as participants were able to select

multiple responses for ethnicity, as applicable

[d] Body build was self-reported by participants

Participant age at the time of taking the survey and at the appearance of initial

symptoms are presented in Fig. 1. The majority of respondents at the time of the survey

 (73.1%) were ≥ 46 years old. At the time of initial symptom onset there is a proportional shift to

377 the younger ages, with more than half (53.6%) ≤ 45 years.

Fig. 1 Comparison of age distribution at time of survey and at onset of symptoms among 1105 participants. Not all participants reported age at symptom onset (n = 1022).

Assessment of symptoms

385   Participants were asked to list their symptoms in order of severity. Almost all

386 participants (99.6%, n = 1101) responded to this question, including 74 respondents who listed

387 no specific symptoms. A total of 712 specific symptoms were described. Fig. 2 displays the 20

388 most frequently reported symptoms and their percentages, with color coding to denote

389 symptoms with STW cross-condition scores ≥ 6 (most indicative for arachnoiditis).

Fig. 2 Most common symptoms among 1101 study participants reporting symptom data.
STW (StuffThatWorks) cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for
arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a
low indication (see Methods). Solid bars represent scores ≥ 6.

Given the large volume of symptoms described (n = 712), the 10% most frequently cited

(n = 71) were categorized into groups of like symptoms using content analysis methodology.

This produced 8 main symptom categories: pain; symptoms of motor nerve damage or

irritation; altered sensation; symptoms experienced in the feet; bladder or bowel issues; head

and neck symptoms; difficulty with daily activities; and "other" (autonomic, gastrointestinal,

endocrine, autoimmune, heat or temperature sensation, and not otherwise categorized).

Analysis of the additional 67 symptoms reported by ≥ 1% of the total study population (i.e. ≥ 11

people) did not yield any further distinct symptom categories beyond those previously

identified.

Table 2 presents the symptoms in each category and corresponding percentages. STW

cross-condition scores (also shown for each symptom), revealed a hierarchy of symptoms

highly indicative of arachnoiditis (scores ≥ 6), with decreasing significance as follows: lower

back pain, legs pain, formication (feeling of something crawling on you), electric shock feeling,

burning sensation in feet, weakness in legs, numbness in feet, bladder issues, numbness in

legs, burning sensation in legs, numbness, back pain, muscle spasms, foot pain, burning

sensation, buttocks pain, shooting leg pain, and tingling sensation. Supplementary Material 2

provides a complete list of all symptoms reported by participants, ordered by frequency (n, %,

STW cross-condition score).

Table 2: Main symptoms by category

Categories	Symptoms					
	Percent of participants (n=1101); STW cross-condition score [a]					
		%	score		%	score
Pain						
Spinal pain	Lower back pain	43.5	**7.21**	Back pain	39.1	**6.86**
	Spine pain	3.3	5.04	Lumbar region pain	3.1	5.65
	Pain across sacrum	2.9	4.99			
Referred pain	Legs pain	41.6	**7.12**	Burning sensation in legs	10.8	**7.00**
	Hip pain	9.6	5.59	Buttocks pain	8.7	**6.24**
	Sciatica	5.9	5.44	Shooting leg pain / radiating pain down leg	4.6	**6.17**
	Nerve pain in legs	4.5	5.25	Radiating pain	4.2	5.00
	Right leg pain	3.5	5.18	Left leg pain	2.9	5.24
	Groin pain	2.9	3.80			
Pain quality	Burning sensation	20.7	**6.34**	Electric shock feeling	18.4	**7.08**
	Sharp / stabbing pain	13.0	5.93	Nerve pain	8.4	5.41
	Burning pain	7.6	5.93	Shooting pains	6.7	5.61
	Stinging	4.9	5.21	Severe pain	4.9	3.08
	Crippling / extreme pain	3.7	5.11			
Pain other	Pain / chronic pain	27.0	3.70	Widespread pain / body aches	3.5	2.73
Motor nerve damage or irritation	Muscle spasms	19.3	**6.64**	Weakness in legs	18.3	**7.01**
	Weakness	12.2	5.01	Foot drop	5.7	5.54
	Neuropathy	5.5	5.38	Leg cramps	5.1	5.23
	Twitching	4.8	5.08	Cramping	4.6	3.14
	Spasms	3.7	3.96	Leg/s spasms	3.4	4.88
Altered sensation	Numbness	30.5	**6.96**	Tingling sensation	18.0	**6.05**
	Numbness in legs	16.4	**7.00**	Formication (feeling of something crawling on you)	15.2	**7.09**
	Tingling legs	7.9	5.50	Pins and needles	5.4	4.79
	Lower leg numbness	4.3	4.74	Water dripping sensation	3.8	5.63
Symptoms in feet	Numbness in feet	17.2	**7.01**	Foot pain	16.6	**6.52**
	Burning sensation in feet	14.4	**7.04**	Tingling feet	6.0	5.06
Bladder or bowel symptoms	Bladder issues (unspecified)	11.9	**7.01**	Incontinence	10.3	5.69
	Bowel issues (unspecified)	6.6	5.20	Fecal incontinence	4.2	5.14
Head and neck symptoms	Headaches	22.3	4.54	Blurred vision	8.0	5.21
	Balance issues / loss of balance	7.5	4.83	Neck pain	6.6	4.37
	Migraines	6.4	3.32	Tinnitus	6.2	4.96
	Dizziness / severe dizziness	4.4	2.32	Brain fog	3.3	2.09
Difficulty with daily activities	Mobility issues / difficulty walking	18.0	5.48	Difficulty standing	9.4	5.82
	Difficulty sitting	7.6	5.61	Pain sitting	3.8	5.44
	Unable to walk / stand	3.0	3.72			
Other	Fatigue	10.9	1.95	Insomnia	4.8	2.54
	Sweating / overheating	4.5	3.55	Depression / feeling depressed	3.9	2.04
	Nausea	3.1	1.72			

418 *n*, number of participants who reported symptom data (1101); *STW*, StuffThatWorks

419 [a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium

420 degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold

Earliest presenting symptoms

Participants were asked to recall whether, prior to diagnosis or early in the condition, there were any symptoms or warning signs that worried them or made them feel something was not right. The majority of participants (92.2%, n = 1019) endorsed early symptoms, reporting 418 symptoms, similar in character to the general arachnoiditis symptoms participants had listed. Pain and altered sensation were predominant among the most common reported early symptoms (14/20 symptoms). An absence of early symptoms was indicated by 8.8% of respondents. The frequency, percent and STW cross-condition score for the 20 most common early symptoms are presented in Table 3. Supplementary Material 3 provides a complete list of all early symptoms reported by participants, ordered by frequency (n, %, STW cross-condition score).

435 **Table 3. Most common early symptoms among 1019 study participants reporting early**

436 **symptoms**

Early symptom	n	%	STW cross-condition score [a]
Pain / chronic pain	172	16.8	5.40
Back pain	110	10.8	**7.03**
None	90	8.8	-
Legs pain	73	7.1	**7.00**
Lower back pain	51	5.0	**7.00**
Mobility issues / difficulty walking	48	4.7	5.17
Numbness	47	4.6	**6.02**
Numbness in legs	44	4.3	**6.72**
Constant pain	41	4.0	5.26
Severe pain	41	4.0	5.07
Burning sensation	39	3.8	5.79
Weakness in legs / jelly legs	36	3.5	**6.07**
Numbness in feet	34	3.3	**6.16**
Deterioration of health / condition / worsening of symptoms	31	3.0	2.82
Electrical shock feeling	30	2.9	**6.10**
Burning sensation in legs	28	2.7	5.92
Surgery induced condition	28	2.7	5.62
Crippling / extreme pain	27	2.6	5.58
Headaches	27	2.6	3.67
Tingling sensation	26	2.5	5.12

n, number of participants with each symptom; *STW*, StuffThatWorks.

[a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has

a medium degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold.

Assessment of aggravating factors

Factors which exacerbated their condition were reported by 95.0% of respondents (n =

1050), comprising 276 different aggravating factors. The 20 most frequently reported

aggravating factors are presented in Fig. 3. "Sitting or sitting too long" and "standing or

standing too long" were the most common aggravating factors, reported by 62.5% and 58.3%

of respondents, respectively, and carried the highest cross-condition scores for aggravating

factors at 7.70 and 7.59, respectively.

Fig. 3 Most common aggravating factors among 1050 study participants reporting aggravating factors. STW (StuffThatWorks) cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Solid bars represent scores ≥ 6.

Analysis revealed 62 exacerbating factors reported by ≥ 1% of participants, stratified into eight discrete categories: positional factors (sitting, standing, or lying down); specific movements or activities; physical exertion intensity; weather or temperature variables; physical or mental health parameters; medical treatment or non-treatment; inactivity; and miscellaneous variables. Table 4 presents these factors by category, including their frequency and STW cross-condition scores. Supplementary Material 4 provides a complete list of all aggravating factors reported by participants, ordered by frequency (n, %, STW cross condition

462   score).

464   **Table 4. Aggravating factors by category**

Categories	Subcategory	Aggravating factors				
		Percent of participants (n=1050); STW cross-condition score [a]				
			%	score		%	score
Positions	Sitting	Sitting or sitting too long	62.5	**7.70**	Car rides / long car rides	3.8	5.04
		Driving	3.8	5.02	Sitting upright	1.6	3.32
	Standing	Standing or standing too long	58.3	**7.59**	Standing still	3.2	5.39
	Lying down	Laying down	7.5	**6.16**	Lying down for long	3.8	5.43
		Lying on back	2.4	4.40	Sleep	1.1	1.56
	General	Being in one position too long	4.5	**6.14**	Certain positions	1.2	2.02
Movements or activities	Walking	Walking	30.6	**7.17**			
	Bending, twisting or stretching	Bending over	22.7	**7.29**	Twisting	5.8	**6.33**
		Stretching	2.4	4.60	Reaching up	1.4	3.81
	Lifting	Lifting	14.2	**7.10**	Heavy lifting	3.5	4.67
		Carrying heavy things	1.1	1.85			
	Transitional movements	Standing up	5.4	**6.54**	Squatting	2.9	5.38
		Stair climbing / going down stairs	1.5	2.61			
	General	Everything / life	3.2	3.57	Certain activities	1.7	1.93
		Housework	1.5	3.36	Cleaning	1.3	2.62
		Gardening	1.0	2.05			
Physical exertion intensity		Walking too much	15.5	**7.08**	Activity / too much activity	12.7	**6.24**
		Excessive movement	10.2	5.76	Physical exertion	10.1	4.73
		Overdoing	7.1	5.61	Physical activity	5.1	4.80
		Exercise	4.1	2.09	Running	2.0	2.95
Weather or temperature		Cold weather	7.5	3.35	Temperature / weather (unspecified)	4.8	3.91
		Weather changes	3.4	4.18	Barometric pressure changes	3.0	4.69
		Heat	2.4	1.65	Humidity	2.2	2.40
		Hot weather	1.5	1.96	Wet weather	1.2	1.85
Physical or mental health parameters		Stress	17.3	1.62	Lack of sleep	3.2	1.49
		Fatigue	2.6	1.70	Pain	2.0	2.86
		Poor sleep	1.2	1.83	Sleep	1.1	1.56
		Falling	1.1	2.42	Anxiety / feeling anxious	1.0	1.22
Medical treatment or non-treatment		Medication (unspecified)	11.8	1.33	Not adhering to treatment	3.4	2.01
		Surgery	1.6	2.84	Lack of treatment	1.1	1.67
Inactivity		Lack of movement	2.8	3.54	Inactivity	2.5	2.43
		Lack of exercise	1.2	1.35			
Miscellaneous		Sugar / too much sugar	2.7	1.61	Menstrual cycle (period)	1.1	1.43
		Alcohol / drinking too much	1.0	1.11	Poor diet	1.0	1.23

465   *n*, number of participants who reported aggravating factors (1050); *STW*, StuffThatWorks.

466   [a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium

467   degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold.

Assessment of comorbid conditions

Participants were asked to list all diagnosed comorbid medical conditions, with 830 (72.2%) respondents reporting at least one such condition. The 20 most common conditions are shown in Table 5 along with their frequency, % and STW cross-condition score. Eight comorbidities were spine-related in origin, seven of which yielded cross-condition scores highly indicative of arachnoiditis.

Table 5. Most common comorbidities among 830 study participants reporting comorbidities

Comorbidity	n	%	STW cross-condition score [a]
Degenerative Disc Disease (DDD)	268	32.3	**7.13**
Spinal stenosis	210	25.3	**7.33**
Fibromyalgia	207	25.0	3.82
Hypertension	112	13.5	2.10
Osteoarthritis	103	12.4	4.97
Arthritis (unspecified)	99	11.9	5.04
Cauda equina syndrome	91	11.0	**7.52**
Scoliosis	85	10.3	5.86
Clinical depression	84	10.1	1.24
Migraine	83	10.0	2.03
Failed back surgery syndrome (FBSS)	82	9.9	**7.43**
Tarlov cysts	81	9.8	**7.39**
Herniated disc	70	8.4	**7.02**
Hypothyroidism	69	8.3	1.72
Anxiety / generalized anxiety disorder (GAD)	68	8.2	1.15
Ehlers Danlos Syndrome (EDS)	66	8.0	4.09
Diabetes mellitus	56	6.8	2.55
Bulging discs	53	6.4	**7.00**
Complex regional pain syndrome	50	6.0	**6.43**
Rheumatoid arthritis	47	5.7	2.93

n, number of participants with each comorbidity; *STW*, StuffThatWorks

[a] STW cross-condition score (scale 1-10): A score ≥ 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods). Scores ≥ 6 are shown in bold

Survey of treatments

The 30 treatments most frequently tried by the 982 participants (88.9%) who responded to this question are shown in Table 6, ordered by self-rated effectiveness (STW estimated ratio). The 90% confidence intervals for rates of effectiveness are generally quite broad, reflecting the relatively small numbers of participants who rated individual treatments as effective.

Among the treatments in Table 6, it can be seen that the most frequently tried treatments are not the same as those self-rated as most effective. The most frequently tried treatments (listed by ≥ 20% of respondents) include gabapentin (37.9%), physiotherapy (30.1%), pregabalin (26.5%), and oxycodone (23.5%). In contrast, the treatments with the highest rated effectiveness (≥ 20% estimated ratios) include low-dose naltrexone (28% effective, tried by only 6.8%), ketamine infusion (24.8%), fentanyl (21.1%), and oxycodone (20.9%).

Table 6. Most frequently tried treatments among 982 study participants reporting treatment data, ranked by self-rated effectiveness

Treatment tried	Total [a] n (%)	Self-rated as effective [b]		
		n	STW estimated ratio (%) [c]	90% CI
Naltrexone hydrochloride (low dose naltrexone)	67 (6.8)	20	28.1	20.0-37.0
Ketamine hydrochloride (ketamine infusions)	65 (6.6)	17	24.8	16.9-33.4
Fentanyl (patch and other routes)	92 (9.4)	20	21.1	14.7-28.1
Oxycodone hydrochloride	231 (23.5)	49	20.9	16.8-25.4
Pain relief medication (unspecified)	97 (9.9)	20	20.1	14.0-26.8
Morphine sulfate	104 (10.6)	21	19.7	13.9-26.2
Spinal cord stimulator (SCS)	119 (12.1)	24	19.7	14.2-25.8
Tizanidine hydrochloride	77 (7.8)	15	18.9	12.4-26.3
Hydrocodone bitartrate	72 (7.3)	12	16.3	10.1-23.5
Stretching	72 (7.3)	11	15.1	9.0-22.1
Magnesium (glycinate and others)	67 (6.8)	10	14.7	8.6-21.9
Paracetamol + oxycodone hydrochloride	64 (6.5)	9	14.0	7.9-21.2
Pregabalin	260 (26.5)	36	13.8	10.5-17.4
Tramadol hydrochloride	109 (11.1)	14	12.9	8.2-18.3
Cannabidiol (CBD)	79 (8.04)	10	12.7	7.4-19.0
Muscle relaxants	65 (6.5)	8	12.4	6.7-19.2
Hydrotherapy	76 (7.7)	9	12.0	6.7-18.2
Massage	94 (9.6)	11	11.8	7.0-17.4
Chiropractic	65 (6.6)	7	11.0	5.7-17.6
Paracetamol + hydrocodone bitartrate	68 (6.9%)	7	10.6	5.4-16.9
Duloxetine hydrochloride	135 (13.7)	14	10.5	6.6-15.0
Baclofen / baclofen intrathecal pump	92 (9.4)	9	10.0	5.6-15.4
Gabapentin	372 (37.9)	37	10.0	7.6-12.7
Turmeric capsules / pills	74 (7.5)	7	9.8	5.0-15.7
Paracetamol (acetaminophen)	76 (7.7)	6	8.4	4.0-13.8
Physiotherapy	296 (30.1)	21	7.2	5.0-9.8
Amitriptyline hydrochloride	81 (8.2)	5	6.8	3.0-11.6
Ibuprofen	88 (9.0)	4	5.2	2.1-9.4
Transcutaneous electrical nerve stimulation	85 (8.7)	3	4.3	1.5-8.2
Acupuncture	90 (9.2)	2	3.1	0.9-6.4

n, number of participants reporting each treatment; *STW*, StuffThatWorks; *CI*, confidence intervals

[a] Tried treatments were 90% normalized by the STW normalization tool (see Methods)

[b] Self-rated effectiveness = "significant improvement of condition"

[c] STW estimated ratio = binomial proportion with 90% confidence intervals (see Methods)

The 30 treatments rated as most detrimental by participants are shown in Table 7. The most detrimental (≥ 20% estimated ratios) are: epidural steroid injections (38.5%), spinal injections (unspecified) (31.1%), myelogram (28.5%), epidural injections (unspecified) (28.2%), surgery (21.7%), and traction (20.4%).

Table 7. Most detrimental treatments among 982 study participants reporting treatment data, ranked by self-rated detriment

Treatment tried	Total[a] n (%)	Self-rated detriment[b]		
		n	STW estimated ratio (%)[c]	90% CI
Epidural steroid injections	37 (3.8)	20	38.5	28.0-49.5
Spinal injections (unspecified)	21 (2.1)	11	31.1	19.6-43.8
Myelogram	7 (0.7)	6	28.5	14.9-44.2
Epidural injections (unspecified)	64 (6.5)	22	28.2	20.4-36.6
Surgery (unspecified)	24 (2.4)	8	21.7	12.1-32.8
Traction	7 (0.7)	4	20.4	8.8-34.8
Recurrent surgeries	10 (1.0)	4	18.1	7.7-31.2
Caudal epidural injection	6 (0.6)	3	17.0	6.3-30.9
Hydrocortisone, incl. cortisone injections	21 (2.1)	5	15.6	7.2-26.0
Spinal cord stimulator (SCS) implant	28 (2.9)	6	15.4	7.6-24.9
Nerve blocks (unspecified)	22 (2.2)	5	15.2	7.0-25.4
Facet joint injection	19 (1.9)	4	13.7	5.7-23.9
Fentanyl (patch and other routes)	91 (9.3)	12	12.0	7.3-17.4
Spinal cord stimulator (SCS)	119 (12.1)	15	11.7	7.5-16.5
Physiotherapy	297 (30.2)	35	11.4	8.6-14.5
Gabapentin	372 (37.9)	37	9.8	7.4-12.3
Chiropractic	66 (6.7)	7	9.6	4.9-15.3
Pregabalin	292 (26.7)	25	9.3	6.6-12.3
Methadone	36 (3.7)	4	9.3	3.8-16.6
Opioids (unspecified)	63 (6.4)	6	8.7	4.2-14.3
Corticosteroids (unspecified), including steroid injections (unspecified)	54 (5.5)	5	8.4	3.8-14.3
Amitriptyline	82 (8.3)	7	8.0	4.1-12.9
Morphine sulfate	104 (10.6)	8	7.4	3.9-11.7
Muscle relaxants	66 (6.7)	5	7.2	3.2-12.3
Duloxetine hydrochloride	136 (13.8)	9	6.5	3.6-10.1
Ketamine hydrochloride (ketamine infusions)	65 (6.6)	4	6.1	2.4-10.9
Naltrexone hydrochloride (low-dose naltrexone)	68 (6.9)	4	5.8	2.4-10.5
Acupuncture	91 (9.3)	4	4.6	1.8-8.3
Pain relief medications (unspecified)	97 (9.9)	4	4.4	1.8-7.9
Oxycodone hydrochloride	230 (23.4)	3	2.0	0.8-3.7

n, number of participants reporting each treatment; *STW*, StuffThatWorks; *CI*, confidence intervals

[a] Tried treatments were 90% normalized by the STW normalization tool (see Methods)

[b] Self-rated detriment = "significant worsening of condition"

[c] STW estimated ratio = binomial proportion with 90% confidence intervals (see Methods)

Comparing Tables 6 and 7, it is evident that for several of the interventions that appear on both lists, reports of an effective versus detrimental effect registered similar numbers. For example, 37 respondents reported that gabapentin was effective, while an equal number

516   reported that it was detrimental.

Discussion

This preliminary investigation represents the most comprehensive observational cross-

sectional study of arachnoiditis documented to date and establishes the foundation for

subsequent analytical frameworks. The patient-centered methodological approach enabled

the assembly of a substantially larger cohort than conventional methods would allow. Our

research not only consolidates what is already known about arachnoiditis but also presents

several new findings.

Prevalence according to demographics

Female participants comprised 75.9% of respondents in our study. This compares with

45.5% in a 2024 systematic review of 147 studies (510 cases) [7], suggesting a more balanced

sex distribution in the broader literature. Other large (n ≥ 80) case series not covered in the

systematic review have shown variable sex distributions, with female proportions ranging from

33% to 81% [4,12,28,34].

The true incidence of arachnoiditis and its sex ratio have not been well defined and may

depend on causal factors, highlighting a need for further epidemiological studies. The marked

female predominance seen in our study may reflect multiple factors. Autoimmunity may play a

role in the pathophysiology of arachnoiditis, and the majority of autoimmune conditions are

more common in females [90,91]. Another risk factor specific to females is obstetric epidural

anesthesia. When carried out properly, epidural anesthesia is an extremely rare cause of

arachnoiditis [30,92,93] however as up to two-thirds of females in developed countries

undergo this procedure during childbirth [94], the sheer volume of cases augments the

prevalence of this complication in proportion to the substantial number of procedures

performed. It is also possible that one of the contributors to sex ratio imbalance in our study

could be related to participation on the STW platform facilitated through social networks, in

which females tend to be more engaged [95,96], although participants joined through multiple

pathways.

In terms of age distribution, 73.1% of our respondents were ≥ 46 years old, which is

older than the mean age of 44.2 years (standard deviation [SD] 17.53) reported in the 2024

systematic review [7]. This difference likely reflects our cross-sectional design, which captures

individuals with established arachnoiditis rather than those at initial diagnosis. However, our

participants' ages fall within the SD of the review findings [7], and align with the

aforementioned case series, which report median or mean ages of 48.4 to 61.3 years

[4,12,28,34]. Importantly, our work adds insight as to the age of initial symptom onset, which is

spread across earlier age groups, with 53.6% ≤ 45 years.

554   Symptoms of arachnoiditis

The arachnoiditis symptoms we report are consistent with previous studies

[1,4,10,12,34], however, our work further elaborates symptom descriptions, and also identifies

which symptoms are most indicative of the condition. Pain and sensory disturbances were

predominant among the most frequently reported symptoms (35/71 symptoms), and included

burning sensations, electric shock sensations, shooting pain, numbness, tingling, and

formication (sensations of insects crawling on the skin). All these symptoms had high STW

cross-conditions scores, suggesting greater specificity for arachnoiditis. Formication has been

described in previous reports [12,34] although it is not unique to arachnoiditis, and has also

been reported with other neurological conditions [97]. Aldrete [12] has proposed

neurophysiological explanations for many of the sensory symptoms in arachnoiditis, including

formication, and also described pain distribution patterns that may not always follow nerve

dermatomes but may be more regional or patchy in nature, reminiscent of findings in tethered

cord syndrome [98,99].

Beyond sensory symptoms, signs of motor nerve damage or irritation are also

frequently reported in our study, including weakness, foot drop, muscle spasms, cramps and

twitching. Muscle related symptoms such as spasms, cramps and fasciculations have been

previously reported [1,12] however they lack detailed characterization in the literature,

warranting more comprehensive study to better understand their pathophysiology, temporal

progression and their relationship to the location of spinal cord involvement. Motor symptoms

suggest that electrodiagnostic tests may be useful, however, it has been noted that such tests

do not produce a consistent pattern that can be identified as arachnoiditis for diagnostic

purposes [3,4,12]. Yet, the potential utility of these tests has not been systematically

investigated in individuals with arachnoiditis, particularly among those with a spectrum of

motor nerve dysfunction, as has been studied in related conditions, such as adult tethered

cord [100], syringomyelia [101], and Tarlov cysts [102,103]. Such research could prove

beneficial for diagnosis, especially in suspected cases, as well as for monitoring disease

progression.

An array of other physical signs and symptoms were described in people living with

arachnoiditis in our cohort. Symptoms localized to the feet were common, with 17.2%

reporting numbness, 16.6% pain, and 14.4% burning sensation, all of which were associated

with high STW cross-condition scores ≥ 6. Exclusion of the more common causes of sensory

dysesthesias in the feet seen in other conditions, along with the presence of other

characteristic findings and risk factors consistent with arachnoiditis, may lead to more

accurate diagnosis and shorten time to diagnosis.

Eight diverse types of head and neck symptoms were reported by study participants, led

by headache (22.3%), however none produced a STW cross-condition score indicating a high

specificity for arachnoiditis. Bladder and bowel symptoms, led by "unspecified bladder issues"

(11.9%) and incontinence (10.3%), have also been reported in many previous studies

[1,12,34,47] with only "unspecified bladder symptoms" producing a cross-condition score ≥ 6.

Earliest presenting symptoms

We sought to characterize the earliest presenting symptoms of arachnoiditis given there

is some evidence that disease progression might be arrested or reversed in some individuals

with early intervention. Early recognition may also provide patients with timely explanations for

their symptoms and help to reduce diagnostic uncertainty. Our preliminary results suggest that

the character and pattern of earliest symptoms do not differ significantly from general reported

symptoms. Pain and altered sensation predominated among the top 20 earliest symptoms.

Future studies will benefit from gathering information about initial symptoms as soon as

possible after diagnosis to gain a more accurate picture of symptom development.

605   Nature of aggravating factors

The most frequently reported aggravating factors, "sitting or sitting too long" and

"standing or standing too long", were reported by 62.5% and 58.3% of the study population,

respectively. The positional nature of these and other commonly reported aggravating factors

is noteworthy, both in our study and in previous reports. Porcelli and Tennant [34] reported that

87.5% of their 80 subjects with lumbosacral arachnoiditis experienced relief of symptoms

upon standing up, 86.3% reported that standing up for too long caused the need to lie down,

and 83.8% of their subjects found that it hurt to lie flat on their back. Similar positional

symptoms have been documented in case reports of arachnoiditis [18,104,105]. The specific

positions that aggravate symptoms may be correlated with the spinal levels that are affected

by arachnoiditis (not assessed in this study), such that the inflamed or adhered nerves are

compressed or stretched in certain positions. In tethered cord syndrome, positional symptoms

caused by elongation of the lumbar spine have been reported [98], and a potentially analogous

mechanism may be relevant in some cases of arachnoiditis. Positional aggravating factors may

also be reflective of their effect in increasing CSF pressure in various parts of the spine against

an arachnoiditis-induced CSF flow disturbance, or they may be suggestive of a particular

complication. In future studies, we intend to correlate the level of spinal involvement with

specific aggravating factors.

Movements that provoked symptoms were categorized as walking, lifting, transitional

movements, and activities that bend, twist or stretch. Symptom exacerbation likely involves

multifactorial mechanisms. For example, when a nerve is inflamed or irritated, it becomes

more sensitive to mechanical forces like stretching or compression [106]. Additionally, in

disease conditions causing mechanical nerve compromise such as tethered cord syndrome or

radiculopathy, stretching of nerve roots contributes to pathophysiology due to limitation in

nerve root movement or temporary ischemic changes [50,107,108], a finding which has been

extended to arachnoiditis [50].

Activities related to lifting may involve additional mechanisms. During lifting the core

abdominal muscles are activated, and in heavy lifting a Valsalva maneuver may also occur.

These muscle activations increase intra-abdominal and intra-thoracic pressure transiently

[109], both of which increase CSF pressure or volume [110–113]. Such changes can alter CSF

flow in individuals with arachnoiditis or increase pressure against the nerve roots, potentially

exacerbating neurologic symptoms. Increases in CSF pressure have been associated with

symptom exacerbation in individuals with related spinal conditions including syringomyelia

[114] and Tarlov cysts [103]. Patients with syringomyelia are generally advised to avoid

deadlifts, as the Valsalva maneuver can result in deleterious syrinx expansion [114].

Spinal comorbidities, which were common among study participants, present

additional complexities when interpreting aggravating factors, as they may share some

positional and movement-related triggers.

Intense physical exertion commonly caused exacerbation of symptoms. While research

shows benefits of physical activity for chronic or neuropathic pain [115–118], low or low-

moderate intensity exercise is typically recommended—aligning with our findings. Individually

tailored recommendations for physical activity and activity modification in individuals with

arachnoiditis are generally advised.

Some aggravating factors described in our study, while commonly reported, showed

low STW cross-condition scores and can be seen across multiple conditions besides

arachnoiditis. These factors include variations in the weather or temperature, poor sleep,

stress, anxiety, and lack of movement.

Our analysis has the potential to facilitate the development of broader and more

precise clinical diagnostic criteria for arachnoiditis based on symptoms and aggravating

factors, improving diagnostic accuracy and differential diagnosis. This would be especially

important for those in whom arachnoiditis is suspected, but there are no correlative signs

evident in radiological studies. Furthermore, reducing or avoiding exposure to an individual's

known aggravating factors has practical relevance for symptom management. Since

neuropathic pain in individuals with arachnoiditis is often delayed in onset and protracted in

duration relative to the inciting activity [1] the empiric pacing of known aggravating activities

requires anticipation to avoid triggering symptom flares.

Comorbid conditions

Coexisting degenerative spine conditions or anatomic abnormalities are frequently

listed as comorbidities in our study, including spinal stenosis, cauda equina syndrome,

scoliosis, and disc-related pathologies such as degenerative disc disease, or herniated or

bulging discs. All of these conditions, except scoliosis, had high STW cross-condition scores,

suggesting they correlate strongly with arachnoiditis. While these conditions have been

associated with lumbar arachnoiditis in many earlier reports [4,7,12,14,28], they also lead to

invasive spinal interventions—a well described risk factor that is often concomitantly reported

in arachnoiditis studies (not ascertained in this study). However, both disc pathology [29,104]

and degenerative spinal conditions [28,39,49,119,120] have also been identified as the sole

apparent risk factor in cases of arachnoiditis with no history of spinal interventions.

In a related finding, Parenti et al. [43] demonstrated that spinal comorbidities in lumbar

arachnoiditis have a significant relationship to arachnoiditis symptom dynamics, suggesting

that integrated treatment of these comorbidities may help mitigate symptom progression.

However, treatment decisions must carefully consider the potential for invasive interventions

to worsen arachnoiditis. Although Palackdharry et al. [1] reported finding no evidence that

surgical procedures (or lumbar puncture) in unaffected adjacent spinal levels worsen existing

arachnoiditis, this was reported without detail. Further studies are required.

Failed back surgery syndrome was listed by 10% of our study participants as a

comorbidity, consistent with previous studies [1,12,14,121]. Failed back surgery syndrome is

an umbrella term for a variety of pathological conditions, including arachnoiditis, that result in

persistent symptoms after spine surgery. The extent to which symptomatic lumbosacral

arachnoiditis may be present prior to spinal surgery is unknown. This may be difficult to

ascertain due to the overlap of symptoms between arachnoiditis and the underlying pathology

necessitating surgery. In their study of patients undergoing surgery for spinal stenosis—a

condition that is both a known cause of arachnoiditis due to mechanical irritation and creates

confounding radiological findings due to the narrowed spinal canal [119,120,122]—Kawauchi

et al. performed pre-operative myeloscopic assessment of the subarachnoid space [71]. They

found that all patients demonstrated some degree of pre-operative arachnoid adhesions,

however those with marked pre-operative adhesions experienced worse outcomes after the

spinal stenosis surgery. Where surgeons are interested in determining if arachnoiditis is

present pre-operatively and radiological findings are ambiguous, the expanded symptoms list

may assist, particularly when patients report additional symptoms more suggestive of

arachnoiditis (for example, burning sensations in the feet, or formication) than those typically

associated with their degenerative condition.

Our study revealed a 9.8% prevalence of Tarlov cysts in our sample, approximately

twice the estimated prevalence in the general population [123], supporting the association of

Tarlov cysts with arachnoiditis proposed in previous reports [34,37,38]. A further 8.0% of

respondents reported a diagnosis of EDS, which is higher than the estimated prevalence of

joint hypermobility spectrum disorders in the general population (3-4%), and considerably

higher than typical rates of EDS [124], consistent with this association in earlier reports

[34,35]. This association, however, was not explicitly noted in a 2017 comprehensive review of

the neurological and spinal manifestations of EDS [125], suggesting it may be

underrecognized. Fibromyalgia was reported as a comorbidity in 25.0% of study participants,

but produced a low STW cross-condition score. Given that fibromyalgia is a diagnosis of

exclusion, with some symptoms overlapping those attributed to arachnoiditis, fibromyalgia

could be misdiagnosed in patients with arachnoiditis. However, fibromyalgia demonstrates

similarly high comorbid rates across various chronic conditions, including inflammatory

arthritis, autoimmune disorders, centralized pain syndromes and neurological diseases, where

it typically adversely affects quality of life and health status in these individuals [126]. The

substantial prevalence of fibromyalgia in our cohort suggests it may represent a genuine and

clinically important comorbidity in arachnoiditis patients.

Depression and anxiety, commonly associated with chronic pain conditions, were also

frequently reported as comorbidities in our study. Even though osteoarthritis, reported by

12.4% of respondents, is highly prevalent in the age-related general population and less

indicative of arachnoiditis according to a low cross-condition score, it should be noted that

people with arachnoiditis and syrinx may experience Charcot-type neuropathic arthropathy in

a variety of joints [127]. Hypertension, another comorbidity with a low cross-condition score, is

also prevalent in the general population. However, episodic or paroxysmal surges of severe

hypertension may be a sign of autonomic dysreflexia in individuals with arachnoiditis or syrinx

[65,128,129]. In future studies, gathering more detailed information regarding comorbidities

will elucidate etiological factors and predisposing conditions.

Tried treatments

Participants in our study attempted a wide range of treatments, including

pharmaceutical analgesics and neuropathic pain-directed medications, muscle relaxants,

interventional pain procedures, over-the-counter pain relievers, cannabinoids, natural

supplements, bio-electrical stimulation treatments, off-label treatments, and physical

therapies. This range highlights that current approaches are predominantly focused on

symptom management rather than addressing underlying inflammatory or disease-modifying

mechanisms.

Confirming the consensus from earlier literature reports [1,3,11,12], our study

demonstrates that arachnoiditis remains challenging to treat. Participant-reported treatment

effectiveness rates ranged from 3.1% to 28.1%, with most treatments showing less than 15%

effectiveness, demonstrating the critical need for developing more effective treatment

strategies for this condition. Importantly, the wide confidence intervals for effectiveness

indicate considerable uncertainty in these estimates, meaning the true rates could be much

lower or higher.

Among the treatments, it is notable that the most frequently tried treatments are not the

same as those rated as most effective. The most commonly tried treatments—gabapentin

(37.9% of participants), physiotherapy (30.1%), and pregabalin (26.5%)—showed relatively

modest effectiveness rates of 10.0%, 7.2%, and 13.8%, respectively. This pattern likely reflects

standard clinical practice, where these treatments are commonly prescribed as first-line

therapies for neuropathic pain due to their established use and familiarity among clinicians. In

contrast, several less frequently used treatments demonstrated higher effectiveness rates.

Low dose naltrexone emerged as the most effective participant-reported treatment

(28.1% effectiveness) while being tried by only 6.8% of participants. Several recent reports

propose naltrexone as a treatment option for arachnoiditis [1,11,34], however there has been

an absence of studies evaluating it in arachnoiditis patients. The preliminary data from our

study suggests that naltrexone offers beneficial effects, with few detrimental reports, making it

an attractive candidate for further study.

Ketamine also showed high participant-reported effectiveness rates (24.8%) while being

tried by only 6.6% of participants. Its limited use likely reflects significant practical constraints,

including controlled substance regulations, requirements for specialized infusion facilities,

and notable side effects. Many of the highest-rated treatments face similar implementation

challenges. These constraints highlight the broader challenge in chronic pain management of

balancing therapeutic efficacy with safety and regulatory concerns.

Spinal cord stimulators (SCS) showed a moderate participant-reported effectiveness

rate of 19.7%, placing them among the more effective treatments within our study. However, a

considerable proportion (11.7%) of individuals who reported using this modality also rated SCS

as detrimental. SCS have been recommended as a treatment modality option for arachnoiditis

[1], although it has been noted that higher effectiveness rates are typically observed among

specially selected patient subgroups. Further investigation into the specific factors

contributing to treatment detriment in individuals with arachnoiditis, including patient

selection criteria and optimal timing of intervention, will be important for future research.

While non-pharmacologic therapies such as stretching, hydrotherapy, and massage

showed only modest effectiveness rates in our study (15.1%, 12.0%, and 11.8%, respectively),

their favorable safety profiles make them important considerations for patient care,

particularly as components of multimodal treatment approaches. Importantly, our findings

from the assessment of aggravating factors indicate that certain physical activities, including

stretching and overexertion, can worsen symptoms in some patients. Therefore, careful

monitoring and gradual, individualized implementation of these therapies is essential.

Beyond the commonly reported treatments in our results, many other medications and

interventions that have been identified as potentially beneficial in recent arachnoiditis papers

were not represented in sufficient numbers in our study population to appear in our results.

These include, but are not limited to, ketorolac [34], diclofenac and other non-steroidal anti-

inflammatories [3,65], corticosteroids [11,34,104,130], electrotherapeutic agents [65],

metformin [1], cerebrolysin [1], eicosapentaenoic acid (fish oil) [104], newer formulations of

curcumins [1,65], cognitive behavioral therapy to help modulate pain perception [3], and

neural mobilization [1,105]. Similarly, many authors recommend multimodal and

interprofessional pain management strategies, however there were not any multi-drug

regimens or combination therapies reported with sufficient frequency to appear in our results.

Notably, the prevalence of corticosteroid use may be underestimated in our sample as

a consequence of steroid medications being listed individually (e.g., dexamethasone,

methylprednisolone) and therefore counted individually rather than as a collective category.

Further, the open-text survey questions did not differentiate between treatments for routine

daily symptom management versus periodic symptom flares. Since corticosteroids are

frequently used to treat symptom flares and reduce inflammation [11,34,65,130], participants

may have considered only their routine treatments when responding.

Analysis of data comparing treatments rated as effective versus detrimental revealed a

paradoxical pattern wherein certain interventions received contradictory evaluations from

different respondents. This may reflect inter-individual physiological differences, variations in

disease severity or stage at the time of treatment, therapeutic efficacy that diminishes over

time, or differences in underlying etiology. Different causes may elicit distinct inflammatory

patterns or therapeutic windows. In the current study, however, we were unable to compare

the efficacy of treatments over time or across different etiologies.

The most detrimental treatments in our study primarily consisted of invasive spinal

interventions, reflecting their shared capacity to induce spinal cord irritation and inflammation

directly though physical or mechanical trauma to already compromised neural tissues. This

finding aligns with existing literature [1] that identifies invasive spinal procedures as risk factors

for arachnoiditis development.

Contribution of artificial intelligence (AI)/machine learning

Natural language processing techniques, coupled with artificial intelligence and machine learning algorithms, facilitate the analysis of extensive datasets, and have the potential to generate valuable and unique insights. The findings from our study offer considerable new details about arachnoiditis and would not have been feasible without an international online platform and the novel AI tools employed. The STW cross-condition score is particularly unique in its ability to compare individual symptoms, comorbidities and aggravating factors across very large numbers of people with and without arachnoiditis on the online platform, with each receiving a score indicating its specificity for the condition.

AI-generated data output, however, requires careful review and interpretation. For example, in the present study, some similar or identical symptoms were tabulated by AI machine learning as separate entities, such as "tingling" and "pins and needles". This may have resulted from an incomplete ability of natural language processing to detect various open-label text terms as being synonymous. Further training of AI may be required to better recognize and properly categorize and group terms. Use of AI and machine learning to process and categorize large datasets and images in future studies may help to further establish accurate diagnostic criteria for arachnoiditis, including improved MRI interpretation [131,132].

Study limitations

The most notable study limitations include reliance on self-reported data with a potential for recall bias. Furthermore, while the use of open-text survey questions enables a wide range of responses to facilitate learning as much as possible about the condition in an

unbiased manner, this approach may be associated with more unintentional omissions

compared to selecting options from a checklist.

This study did not address the duration, frequency and severity of symptoms, including

symptom flares, and therefore cannot provide an overview of how pain and other symptom

patterns differ between participants. In addition, the aggregate nature of the data provided,

combined with the absence of data on disease location, extent, or suspected causes,

prevented analysis by these variables, which may have yielded valuable insights.

As a cross-sectional study, our data on treatment effectiveness do not offer the same

level of evidence as controlled clinical trials, and the binary effectiveness measure (self-

reported significant improvement of condition) may underestimate treatments that provide

modest but clinically relevant symptom relief. However, our aggregated findings may reveal

meaningful trends and identify treatments suitable for future studies or individual trials.

Assessment of treatment effectiveness is also complicated by the poorly defined natural

history of arachnoiditis, often punctuated by symptom flares, and in which some individuals

experience disease progression, whereas others remain static [2,4]. Treatments that

successfully prevent deterioration rather than provide improvement may represent meaningful

clinical success in some patients but may not be assessed as such. In addition, given that our

results revealed a wide variety of treatments being used, a further limitation is that our data for

effectiveness is limited to the 30 most frequently reported treatments. As a consequence, less

frequently used but potentially more effective treatments may not have been captured.

Specific adverse events or detrimental responses that might have led to discontinuation of a

given treatment were beyond the scope of this present study, as were questions that could link

specific treatments or sequencing of treatments to the early or advanced stage of disease for

an individual.

Generalizability of our findings may be limited given that participation on the STW

platform was driven in part by social media engagement, which tends to favor females and

those with higher socioeconomic backgrounds [133]. In a similar vein, the majority of our

respondents were of white/European ethnicity, which may be related to the survey being

available only in the English language, or potentially also to the lower rates of social media

involvement among other ethnic groups [134]. Similarly, completion of online questionnaires

requires digital literacy and stamina, which could prevent those with significant disability

levels from responding. Despite the potential for selection bias and lack of full representation

of the entire population of those living with arachnoiditis, our findings remain consistent with

earlier reports.

Future directions

Significant areas of unmet need include consensus development of diagnostic criteria

to reduce delays in diagnosis, establishment of natural history studies to better delineate

differences between individuals in initiation and progression of disease, and discovery and

development of more effective treatments.

Greater awareness of arachnoiditis and its causes, along with the development of more

explicit diagnostic criteria, will aid in accelerating diagnosis and reducing the diagnostic

"odyssey" so common in rare diseases [135,136]. Such enhanced recognition by the broader

medical community, and improved understanding of the complications, can bring about a

three-fold benefit. First, to highlight the essential need for multi-disciplinary care; second, to

stimulate pharmaceutical industry and stakeholder interest in initiating and funding

therapeutic research; and third, importantly, to benefit those individuals living with

arachnoiditis who are actively seeking care, to be heard and understood by health care

providers. With more information and training, providers may be less likely to be dismissive of

persons affected by the condition, whose disabling symptoms frequently remain externally

invisible to others, or to misattribute these symptoms to mental health issues or drug-seeking

behavior [1,12,137–139].

The development of novel, more effective treatments for arachnoiditis must be a high

priority as the science and understanding of modulating neuropathic and centrally mediated

pain advance [73]. Given the inflammatory origin of arachnoiditis, future studies might explore

whether medications that target inflammation and effectively cross the blood-brain barrier

might both relieve symptoms and modify disease progression [1,16,73,140]. Treatments that

prevent, stop or reverse fibrotic transformation and its consequences should be a high priority

[1]. Advancements in minimally invasive spinal surgery are promising and may offer new

treatment avenues for arachnoiditis patients in the future, with reduced morbidity [1]. The

development of validated quality-of-life measures specifically designed for assessing

interventions, like those recently developed for Tarlov cyst surgery [141], would significantly

enhance our ability to measure treatment outcomes.

Research should focus not only on developing more effective therapies, but also on

identifying biomarkers or clinical predictors that can guide personalized treatment selection,

particularly given the potential timing-dependent efficacy of some treatments, and the

substantial inter-individual variation in treatment responses observed in our study. In one

example of such translational research, Zhang et al. [16] recently delineated differential gene

expression from multiple cell types in human arachnoid tissues obtained from patients with

and without arachnoiditis undergoing neurosurgery for Chiari malformation or syringomyelia.

They employed transcriptome profiling using sn-RNA seq analysis, providing an avenue of

discovery for new insights into the pathophysiology and signaling pathways characterizing

adhesive arachnoiditis, with the possibility of biomarker discovery.

To support such research endeavors, an arachnoiditis international patient registry

would enable comprehensive data collection across diverse populations over time and

facilitate cross-disciplinary research collaboration. Such a registry could inform future

prospective study design by employing a relational database in which sequential treatments

are linked with clinical disease stage and treatment outcomes. Quantification of treatment

effects can be accomplished through incorporation of validated patient reported outcome

instruments evaluating quality of life, pain, disability, and health-related economic costs. It

would be advantageous to store select anonymized patient health data such as MRI, EMG and

other reports to confirm diagnosis, clarify clinical findings and elaborate upon patient

generated data. Serial collection of longitudinal data on symptoms and level of disability would

help to better define the natural history of progression in our sample. This would also permit

interrogation of the larger dataset to explore any correlations that may exist between the

presumptive inciting causes of an individual's arachnoiditis, the disease distribution within the

spinal cord, and the stage and severity of the condition. Such an approach might also enable

exploration of whether certain subsets of patients respond differentially to various treatments

or experience different rates of disease progression.

Conclusion

This report describes the largest reported observational study on arachnoiditis to date. Our findings consolidate existing knowledge about the condition while advancing new and important observations regarding age of first symptom onset, range of symptoms, aggravating factors, comorbid conditions and self-assessment of tried treatments. Through the application of novel AI/machine learning algorithms we generated unique insights into symptom profiles, treatment patterns and diagnostic indicators for arachnoiditis, offering clinicians practical tools to improve diagnosis and management.

This work establishes a novel methodological approach to assembling a large patient cohort for rare disease research—a substantially larger cohort than would be possible through conventional methods. This advocacy-enabled, patient-centered model illustrates how rare disease advocacy networks can enable the large-scale data collection necessary for meaningful discovery in a condition that remains understudied and underdiagnosed.

Supplementary Information

Supplementary Material 1. The StuffThatWorks (STW) survey questions used for the data collection for this analysis (PDF file).

Supplementary Material 2. A complete list of all symptoms reported by study participants, ordered by frequency (XLXS file). Includes frequency (n), percent, and STW cross-condition scores.

Supplementary Material 3. A complete list of all early symptoms reported by study

participants, ordered by frequency (XLXS file). It includes frequency (n), percent, and STW

cross-condition scores.

Supplementary Material 4. A complete list of all aggravating factors reported by study

participants, ordered by frequency (XLXS file). It includes frequency (n), percent, and STW

cross-condition scores.

946 Abbreviations

ACMCRN   Arachnoiditis and Chronic Meningitis Collaborative Research Network

AI   Artificial intelligence

CSF   Cerebrospinal fluid

EDS   Ehlers Danlos Syndrome

MRI   Magnetic resonance imaging

SCS   Spinal cord stimulator

STW   StuffThatWorks

955 Declarations

956 Ethics approval and consent to participate

This study involved secondary analysis of de-identified, aggregated data from the

StuffThatWorks digital health platform. The use of these data for research was approved by the

Helsinki/ Ethics Committee at Sheba Medical Center, Israel (protocol #7356-20-SMC). Before

sharing any data, all participants provided digital consent upon platform registration by

agreeing to the platform's terms of use and privacy policy, which informed them that their de-

identified data may be used for research purposes, including by external researchers. The

approving ethics committee deemed this prospective consent adequate and approved a

waiver of requirement for additional consent for use of data from its medical questionnaire for

research purposes, further stipulating that any data shared with external researchers must be

in aggregate form only. Further details are provided in the Methods section.

Consent for publication

Not applicable. The manuscript does not contain any identifiable individual data.

Availability of data and materials

All aggregated data generated or analyzed during this study are included in this published

article and its supplementary information files.

Competing interests

NM participates on the Medical Advisory Board for StuffThatWorks. ED was employed by

StuffThatWorks at the time of this study and was responsible for data extraction. The remaining

authors declare that they have no competing interests.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

Conceptualization: LV, NM, MB, PG, LB. Data curation: ED, MB, SS, LB. Formal analysis: ED, MB, IS, LB. Investigation: LV, ED, PG. Methodology: LV, NM, ED, MB, LB. Resources: LV, DRB, SS. Supervision: LV, LB. Visualization: NM, MB, DRB, SS, LB. Writing – original draft: MB, LB, NM, RS. Writing – review & editing: LV, NM, ED, RS, MB, PG, DRB, SS, LB. All authors have read and approved the final manuscript.

Acknowledgements

The authors wish to thank all the individuals living with arachnoiditis who participated on the STW platform. We acknowledge StuffThatWorks Ltd for use of their digital platform, data aggregation and insights generation. We are grateful to Eve Blackburn for her efforts in raising awareness of the STW platform among individuals with arachnoiditis. We thank Michele Hansen PhD MPH and Richard Dobson MD for reviewing the manuscript, and Rob Lloyd PhD for his review of the CSF dynamics content. We are grateful to Enoch Carter for assistance with data preparation. We appreciate the continuing graphic design support of Matthew Churchward and Eve Blackburn. We dedicate this paper to the memory of ACMCRN co-founder and former VP of Research, Terri Lewis, PhD.

Authors' information

[1] Arachnoiditis and Chronic Meningitis Collaborative Research Network (ACMCRN), London, Ontario, Canada

[2] Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

[3] Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel

[4] StuffThatWorks Ltd, Tel Aviv, Israel

[5] Department of Neurology, Sheba Medical Center, Ramat Gan, Israel

[6] Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada

References

[1] Palackdkharry CS, Wottrich S, Dienes E, Bydon M, Steinmetz MP, Traynelis VC. The leptomeninges as a critical organ for normal CNS development and function: first patient and public involved systematic review of arachnoiditis (chronic meningitis). PLOS One 2022;19. doi: 10.1371/journal.pone.0274634. PMID: 36178925.

[2] Mastorakos P, Jonathan Pomeraniec I, Bryant JP, Chittiboina P, Heiss JD. Flexible thecoscopy for extensive spinal arachnoiditis. J Neurosurgery Spine 2022;36:325–35. doi: 10.3171/2021.4.SPINE21483. PMID: 34598155.

[3] Peng H, Conermann T. Arachnoiditis. StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

[4] Long DM. Chronic adhesive spinal arachnoiditis: pathogenesis, prognosis, and treatment. Neurosurg Q 1992;2:296–320.

[5] Holmström U, Tsitsopoulos PP, Flygt H, Holtz A, Marklund N. Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients. Spinal Cord 2018;56:873–882. doi: 10.1038/s41393-018-0094-y. PMID: 29588484.

1028   [6]   Inoue Y, Nemoto Y, Ohata K, Daikokuya H, Hakuba A, Tashiro T, et al. Syringomyelia
1029   associated with adhesive spinal arachnoiditis: MRI. Neuroradiology 2001;43:325–30. doi:
1030   10.1007/pl00006049. PMID: 11338419.

1031   [7]   Zhang W, Liu Z, Wang K, Zhang L, Liu S, Zhang X, et al. Spinal adhesive arachnoidopathy,
1032   the disorder more than simply adhesive arachnoiditis: a comprehensive systematic
1033   review of 510 cases. CNS Neurosci Ther 2024;30:e70084. doi: 10.1111/CNS.70084. PMID:
1034   39435986.

1035   [8]   Wang R, Zhou R, Chen Z, Gao S, Zhou F. The glial cells respond to spinal cord injury. Front
1036   Neurol 2022;13. doi: 10.3389/fneur.2022.844497. PMID: 35599739.

1037   [9]   Holmström U, Tsitsopoulos PP, Holtz A, Salci K, Shaw G, Mondello S, et al. Cerebrospinal
1038   fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and
1039   neurological deterioration. Acta Neurochir (Wien) 2020;162:2075–86. doi:
1040   10.1007/S00701-020-04422-6. PMID: 32588294.

1041   [10]   Anderson TL, Morris JM, Wald JT, Kotsenas AL. Imaging appearance of advanced chronic
1042   adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol 2017;209:648–55.
1043   doi: 10.2214/AJR.16.16704. PMID: 28639826.

1044   [11]   Maillard J, Batista S, Medeiros F, Farid G, Santa Maria PE, Perret CM, et al. Spinal adhesive
1045   arachnoiditis: a literature review. Cureus 2023;15:e33697. doi: 10.7759/cureus.33697.
1046   PMID: 36788823.

1047   [12]   Aldrete J. Suspecting and diagnosing arachnoiditis. Pract Pain Manag 2006;6.

1048   [13]   Guyer DW, Wiltse LL, Eskay ML, Guyer BH. The long-range prognosis of arachnoiditis.
1049   Spine (Phila Pa 1976) 1989;14:1332–41. doi : 10.1097/00007632-198912000-00010.
1050   PMID: 2617363.

1051   [14]   Burton C V. Lumbosacral arachnoiditis. Spine (Phila Pa 1976) 1978;3:24–30. doi:
1052   10.1097/00007632-197803000-00006. PMID: 148106.

1053   [15]   Orphanet. Arachnoiditis 2024. https://www.orpha.net/en/disease/detail/137817.

1054   [16]   Zhang W, Zhang X, Wang K, Liu Z, Zhang L, Liu S, et al. Single-nucleus transcriptome
1055   profiling provides insights into the pathophysiology of adhesive arachnoiditis. Biochim
1056   Biophys Acta Mol Basis Dis 2025;1871. doi: 10.1016/j.bbadis.2024.167655. PMID:
1057   39755217.

1058   [17]   Brodbelt AR, Stoodley MA. Post-traumatic syringomyelia: A review. Journal of Clinical
1059   Neuroscience 2003;10:401–8. doi: 10.1016/S0967-5868(02)00326-0. PMID: 12852875.

1060   [18]   Jain N, Jaunozolina L, Putraima I, Auslands K, Millers A. Delayed spinal arachnoiditis with
1061   syringomyelia following aneurysmal subarachnoid haemorrhage: a case report with
1062   patient experience. Spinal Cord Ser Cases 2024;10. doi:/ 10.1038/S41394-024-00654-1.
1063   PMID: 38858362.

1064 1065 1066	[19]	Laitt R, Jackson A, Isherwood I. Patterns of chronic adhesive arachnoiditis following Myodil myelography: the significance of spinal canal stenosis and previous surgery. Br J Radiol 1996;69:693–8. doi:10.1259/0007-1285-69-824-693. PMID: 8949669.
1067 1068 1069	[20]	Nadeem SF, Baig AN, Tariq QUA, Shamim MS. Spinal arachnoiditis and syringomyelia: review of literature with emphasis on postinfectious inflammation and treatment. Surg Neurol Int 2022;13. doi: 10.25259/SNI_383_2022. PMID: 35928312.
1070 1071 1072 1073	[21]	Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol 2022;157:533–50. doi: 10.1007/s11060-022-03997-7. PMID: 35416575.
1074 1075 1076	[22]	Di Ieva A, Barolat G, Tschabitscher M, Rognone E, Aimar E, Gaetani P, et al. Lumbar arachnoiditis and thecaloscopy: brief review and proposed treatment algorithm. Cent Eur Neurosurg 2010;71:207–12. doi: 10.1055/s-0029-1243201. PMID: 20027540.
1077 1078 1079	[23]	Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. New England Journal of Medicine 2012;367:2194–203. doi: 10.1056/nejmoa1212972. PMID: 23131029.
1080 1081 1082	[24]	Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, Duwve J, et al. Fungal infections associated with contaminated methylprednisolone injections. New England Journal of Medicine 2013;369:1598–609. doi: 10.1056/nejmoa1213978. PMID: 23252499.
1083 1084 1085	[25]	Centers for Disease Control and Prevention. Spinal and paraspinal infections associated with contaminated methylprednisolone acetate injections – Michigan, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013 May 17;62(19):377-8.
1086 1087 1088	[26]	World Health Organization. WHO. 2023. Outbreak of suspected fungal meningitis associated with surgical procedures performed under spinal anaesthesia in US & Mexico 2023.
1089 1090 1091 1092 1093 1094	[27]	Practice advisory for the prevention, diagnosis, and management of infectious complications associated with neuraxial techniques: an updated report by the American Society of Anesthesiologists Task Force on Infectious Complications Associated with Neuraxial Techniques and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2017;126:585–601. doi: 10.1097/ALN.0000000000001521. PMID: 28114178.
1095 1096 1097	[28]	El Homsi M, Gharzeddine K, Cuevas J, Arevalo-Perez J, Rebeiz K, Khoury NJ, et al. MRI findings of arachnoiditis, revisited. Is classification possible? Journal of Magnetic Resonance Imaging 2021;54:904–9. doi: 10.1002/jmri.27583. PMID: 33644967.
1098 1099	[29]	Ottaiano AC, de Freddi TAL. "Sticky Spine": A review of the imaging findings for spinal arachnoiditis. Neurographics 2022;12:169–75. doi: 10.3174/ng.2100062.
1100 1101 1102	[30]	Brenna CTA, Khan S, Poots C, Brull R. Association between perioperative neuraxial local anesthetic neurotoxicity and arachnoiditis: a narrative review of published reports. Reg Anesth Pain Med 2024;49:726–50. doi: 10.1136/RAPM-2023-104941. PMID: 38050164.

[31] De La Motte MB, Abbas R, Jouan F, Van Gysel D, Chauveheid MP, Papo T, et al. Systemic
inflammatory disorders in patients admitted for aseptic meningitis. Clin Med
2018;18:132–137. doi: 10.7861/CLINMEDICINE.18-2-132. PMID: 29626017.

[32] Abhinav K, Bradley M, Aquilina K, Patel NK. Spinal arachnoiditis and cyst formation with
subarachnoid haemorrhage. Br J Neurosurg 2012;26:574–5. doi:
10.3109/02688697.2011.651512. PMID: 22299598.

[33] Khan MU, Anthony J, Devlin J, Fraser A. Adhesive arachnoiditis in mixed connective tissue
disease: a rare neurological manifestation. BMJ Case Rep 2016. doi: 10.1136/bcr-2016-
217418. PMID: 27986694.

[34] Porcelli MJ, Tennant FS. Primer on Adhesive Arachnoiditis. JOFP-CA 2024;2. doi:
10.58858/010203.

[35] Tonk SS, Wilson GN. Similar Ehlers–Danlos Syndrome profiles produced by variants in
multiple collagen genes. DNA 2025;5:11. doi: 10.3390/DNA5010011.

[36] Pasoglou V, Janin N, Tebache M, Tegos TJ, Born JD, Collignon L. Familial adhesive
arachnoiditis associated with syringomyelia. American Journal of Neuroradiology
2014;35:1232–6. doi: 10.3174/ajnr.A3858. PMID: 24481329.

[37] Luchtmann M, Klammer A, Iova MA, Roth A, Mawrin C, Warnke JP. Combined endoscopic
and microsurgical treatment of Tarlov cysts. Interdisciplinary Neurosurgery
2024;36:101925. doi: 10.1016/j.inat.2023.101925.

[38] Vaughan D, Bolger C, O'Brien DF. An interesting case of primary spinal arachnoiditis. Br J
Neurosurg 2012;26:555–7. doi: 10.3109/02688697.2012.663516. PMID: 22369357.

[39] Arai A, Aihara H, Miyake S, Hanada Y, Kohmura E. Syringomyelia due to thoracic spinal
stenosis with ossified ligamentum flavum. Neurol Med Chir 2011;51:157–9. doi:
10.2176/NMC.51.157. PMID: 21358164.

[40] Ross JS, Masaryk TJ, Modic MT, Delamater R, Bohlman H, Wilbur G, et al. MR imaging of
lumbar arachnoiditis. AJR Am J Roentgenol 1987;149:1025–32. doi:
10.2214/AJR.149.5.1025. PMID: 3499773

[41] Hoffman G.S, Ellsworth C.A, Wells E.E, Franck W.A, Mackie R.W. Spinal arachnoiditis.
what is the clinical spectrum? II. Arachnoiditis induced by Pantopaque/autologous blood
in dogs, a possible model for human disease. Spine (Phila Pa 1976) 1983;8:541–51. PMID:
6648703

[42] Delamarter RB, Ross JS, Masaryk TJ, Modic MT, Bohlman HH. Diagnosis of lumbar
arachnoiditis by magnetic resonance imaging. Spine (Phila Pa 1976) 1990;15:304–10. doi:
10.1097/00007632-199004000-00011. PMID: 2353276.

[43] Parenti V, Huda F, Richardson PK, Brown D, Aulakh M, Taheri MR. Lumbar arachnoiditis:
does imaging associate with clinical features? Clin Neurol Neurosurg 2020;192. doi:
10.1016/j.clineuro.2020.105717. PMID: 32062307.

[44] Klekamp J. Treatment of syringomyelia related to nontraumatic arachnoid pathologies of
the spinal canal. Neurosurgery 2013;72:376–89. doi: 10.1227/NEU.0b013e31827fcc8f.
PMID: 23208064.

[45] Davidoff CL, Liu S, Wong JHY, Koustais S, Rogers JM, Stoodley MA. Treatment of
syringomyelia in patients with arachnoiditis at the craniocervical junction. World
Neurosurg 2017;107:565–73. doi: 10.1016/j.wneu.2017.08.064. PMID: 28842236.

[46] Moura da Silva LF, Buffon VA, Coelho Neto M, Ramina R. Non-schwannomatosis lesions
of the internal acoustic meatus - a diagnostic challenge and management: a series report
of nine cases. Neurosurg Rev 2015;38:641–8. doi : 10.1007/S10143-015-0638-Y. PMID:
25957055.

[47] Epstein NE, Agulnick MA. Perspective: Lumbar adhesive arachnoiditis (AA)/ chronic AA
(CAA) are clinical diagnoses that do not require radiographic confirmation. Surg Neurol Int
2022;13. doi: 10.25259/SNI_943_2022. PMID: 36447842.

[48] Warnke JP, Köppert H, Bensch-Schreiter B, Dzelzitis J, Tschabitscher M. Thecaloscopy part
III: First clinical application. Minimally Invasive Neurosurgery 2003;46:94–9. doi:
10.1055/S-2003-39341. PMID: 12761680.

[49] Tobita T, Okamoto M, Tomita M, Yamakura T, Fujihara H, Baba H, et al. Diagnosis of spinal
disease with ultrafine flexible fiberscopes in patients with chronic pain. Spine (Phila Pa
1976) 2003;28:2006–12. doi: 10.1097/01.BRS.0000083595.10862.98. PMID: 12973149.

[50] Berthelot JM, Laredo JD, Darrieutort-Laffite C, Maugars Y. Stretching of roots contributes
to the pathophysiology of radiculopathies. Joint Bone Spine 2018;85:41–5. doi:
10.1016/J.JBSPIN.2017.01.004. PMID: 28115269.

[51] Aldrete J A. Nerve root "irritation" or inflammation diagnosed by magnetic resonance
imaging. Anesthesiology 2003;98:1294. doi: 10.1097/00000542-200305000-00040. PMID:
12717159.

[52] Villani LA, Digre KB, Cortez MM, Bokat C, Rassner UA, Ozudogru SN. Arachnoiditis, a
complication of epidural blood patch for the treatment of low-pressure headache: a case
report and systematic review. Headache 2021;61:244–52. doi: 10.1111/head.14076.
PMID: 33583044.

[53] Her YF, McWilliams RT, Ovrom EA, Watson JC. Corticosteroid therapy in acute and
subacute arachnoiditis – a case series. Int Med Case Rep J 2024;17:235–40. doi:
10.2147/IMCRJ.S445705. PMID: 38559495.

[54] Iqbal IM, Morris R, Hersch M. Adhesive arachnoiditis following inadvertent epidural
injection of 2% chlorhexidine in 70% alcohol—partial recovery over the ensuing eight
years. Anaesth Intensive Care 2018;46:572–4. doi: 10.1177/0310057X1804600606. PMID:
30447665.

[55] Tseng SH, Lin SM. Surgical treatment of thoracic arachnoiditis with multiple subarachnoid
cysts caused by epidural anesthesia. Clin Neurol Neurosurg 1997;99:256–8. doi:
10.1016/S0303-8467(97)00086-3. PMID: 9491300.

[56]   Gottschalk A, Schmitz B, Mauer UM, Bornstedt A, Steinhoff S, Danz B, et al. Dynamic
visualization of arachnoid adhesions in a patient with idiopathic syringomyelia using high-
resolution cine magnetic resonance imaging at 3T. J of Magn Reson Imaging 2010;32:218–
22. doi: 10.1002/JMRI.22207. PMID: 20575079.

[57]   Hatano K, Ohashi H, Kawamura D, Isoshima A, Nagashima H, Tochigi S, et al. MRI
characteristics of syringomyelia associated with foramen magnum arachnoiditis:
differentiation from Chiari malformation. Acta Neurochir (Wien) 2021;163:1593–601. doi:
10.1007/S00701-021-04845-9. PMID: 33881607.

[58]   Ikushima I, Korogi Y, Hirai T, Yamashita Y. High-resolution constructive interference in a
steady state imaging of cervicothoracic adhesive arachnoiditis. J Comput Assist Tomogr
2007;31:143–7. doi: 10.1097/01.RCT.0000230006.46145.16. PMID: 17259847.

[59]   Tu YT, Chiang YH, Lin JH. Delta cord as a radiological localization sign of postoperative
adhesive arachnoiditis: a case report and literature review. Diagnostics (Basel) 2023;13.
doi: 10.3390/DIAGNOSTICS13182942. PMID: 37761311.

[60]   Tsuchida R, Sumitani M, Azuma K, Abe H, Hozumi J, Inoue R, et al. A novel technique
using magnetic resonance imaging in the supine and prone positions for diagnosing
lumbar adhesive arachnoiditis: a preliminary study. Pain Practice 2020;20:34–43. doi :
10.1111/papr.12822. PMID: 31325409.

[61]   Warnke JP, Mourgela S. Lumbale adhäsive arachnoiditis. Endoskopische
subarachnoepidurostomie als neue behandlungsmöglichkeit [adhesive lumbar
arachnoiditis. Endoscopic subarachnoepidurostomy as a new treatment]. Nervenarzt
2007;78:1182–7. doi: 10.1007/s00115-007-2289-x.

[62]   Warnke JP, Mourgela S. Endoscopic treatment of lumbar arachnoiditis. Minimally Invasive
Neurosurgery 2007;50:1–6. doi: 10.1055/s-2007-970056. PMID: 17546535.

[63]   Petrasic JR, Chhabra A, Scott KM. Impact of MR neurography in patients with chronic
cauda equina syndrome presenting as chronic pelvic pain and dysfunction. AJNR Am J
Neuroradiol 2017;38:418–22. doi: 10.3174/AJNR.A4994. PMID: 28059708.

[64]   Hackert J, Maßmann L, Sure U, Forsting M, Kleinschnitz C, Pul R, et al. Immunotherapies
in chronic adhesive arachnoiditis - a case series and literature review. ENeurologicalSci
2021;24. doi: 10.1016/j.ensci.2021.100350. PMID: 34195394.

[65]   Tennant F, Porcelli M, Guess S. Adhesive arachnoiditis: no longer a rare disease.
MedCentral 2020;20.

[66]   Gonzalez M. CE, Enriquez LE, Cruz A. C. Arachnoiditis following spinal anesthesia for
Cesarean section. Colombian Journal of Anesthesiology 2012;40:150–2. doi:
10.1016/S2256-2087(12)70031-7.

[67]   Assey E V., Sadiq AM, Swai MJ, Sadiq AM, Dekker MCJ. Idiopathic arachnoiditis of the
cauda equina: a case report from Tanzania. Case Rep Neurol 2021;13:535–40. doi:
10.1159/000518379. PMID: 34720959.

[68] Iwatsuki K, Yoshimine T, Ohnishi YI, Ninomiya K, Moriwaki T, Ohkawa T. Syringomyelia
associated with spinal arachnoiditis treated by partial arachnoid dissection and syrinx –
far distal subarachnoid shunt. Clin Med Insights: Case Rep 2014;7:107–10. doi:
10.4137/CCRep.S14895. PMID: 25232285.

[69] Mauer UM, Gottschalk A, Kunz U, Schulz C. Arachnoscopy: A special application of spinal
intradural endoscopy. Neurosurg Focus 2011;30. doi: 10.3171/2011.1.FOCUS10291.
PMID: 21456934.

[70] Peek RD, Thomas JC, Wiltse LL. Diagnosis of lumbar arachnoiditis by myeloscopy. Spine
(Phila Pa 1976) 1993;18:2286–9. doi: 10.1097/00007632-199311000-00025. PMID:
8278848.

[71] Kawauchi Y, Yone K, Sakou T. Myeloscopic observation of adhesive arachnoiditis in
patients with lumbar spinal canal stenosis. Spinal Cord 1996;34:403–10. doi:
10.1038/SC.1996.72. PMID: 8963995.

[72] Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell M V, Buenaventura RM, et al. An
update of comprehensive evidence-based guidelines for interventional techniques in
chronic spinal pain. Part II: guidance and recommendations. Pain Physician 2013;16:S49–
283. doi: 10.36076/ppj.2013/16/S49. PMID: 23615883.

[73] Shinu P, Morsy MA, Nair AB, Mouslem AKA, Venugopala KN, Goyal M, et al. Novel
therapies for the treatment of neuropathic pain: potential and pitfalls. J Clin Med 2022;11.
doi: 10.3390/jcm11113002. PMID: 35683390.

[74] Day P. Arachnoiditis: A brief summary of the literature. NZHTA Report 2001.

[75] Petty PG, Hudgson P, Hare WSC. Symptomatic lumbar spinal arachnoiditis: Fact or
fallacy? Journal of Clinical Neuroscience 2000;7:395–9. doi: 10.1054/jocn.1999.0223.
PMID: 10942659.

[76] Li T, Wang Y. A Global bibliometric study of spinal arachnoiditis: research trends and
future directions. World Neurosurg 2025;194. doi: 10.1016/j.wneu.2024.123587. PMID:
39710197.

[77] Faigenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network
approach: a new framework to accelerate Castleman's disease and other rare disease
research. Lancet Haematol 2016; 3:e150-2. doi: 10.1016/S2352-3026(16)00007-7. PMID:
33523193

[78] Geraci J, Bhargava R, Qorri B, Leonchyk P, Cook D, Cook M, et al. Machine learning
hypothesis-generation for patient stratification and target discovery in rare disease: our
experience with Open Science in ALS. Front Comput Neurosci 2024;17. doi:
10.3389/fncom.2023.1199736. PMID: 38260713.

[79] Arachnoiditis and Chronic Meningitis Collaborative Research Network. ACMCRN |
Empowering arachnoiditis patients through research, advocacy & support 2025.
https://www.acmcrn.org/.

[80] StuffThatWorks. Introduction & overview | StuffThatWorks | crowdsourcing treatments
that work 2024. https://www.stuffthatworks.health/introduction.

[81] Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for
studying treatments for rare diseases: Methodological review. BMJ 2014;349. doi:
10.1136/bmj.g6802. PMID: 25422272.

[82] Barak-Levitt J, Held R, Synett Y, Kremer N, Hodak E, Sherman S. Hidradenitis suppurativa
international online community: patient characteristics and a novel model of treatment
effectiveness. Acta Derm Venereol 2022;102. doi: 10.2340/actadv.v102.1056. PMID:
35312027.

[83] Engel T, Dotan E, Synett Y, Held R, Soffer S, Ben-Horin S, et al. Self-reported treatment
effectiveness for Crohn's disease using a novel crowdsourcing web-based platform.
United European Gastroenterol J 2023;11:621–32. doi: 10.1002/ueg2.12424. PMID:
37370250.

[84] Held R, Blankstein A. Plantar fasciitis: a novel crowdsourcing approach to data collection
and analysis. J Musculoskelet Res 2021;24. doi: 10.1142/S0218957721500238.

[85] Vears D, Gillam L. Inductive content analysis: A guide for beginning qualitative
researchers 2022;23. doi: 10.11157/fohpe.v23i1.544.

[86] Innovation and Value Initiative, EveryLife Foundation for rare disease. Valuing rare disease
treatments in healthcare: Real Experience, Real Impact. 2024.

[87] McQueen RB, Mendola ND, Jakab I, Bennett J, Nair K V., Németh B, et al. Framework for
patient experience value elements in rare disease: a case study demonstrating the
applicability of combined qualitative and quantitative methods. Pharmacoecon Open
2023;7:217–28. doi: 10.1007/s41669-022-00376-w. PMID: 36316575.

[88] Alifia RR, Sadeghi M, Eluru M, Jafari M, Grando MA. Bridging ethical gaps in digital health
research: a framework for informed consent aligned with NIH guidance. BMC Medical
Ethics 2025; 26:132. doi: 10.1186/s12910-025-01291-S. PMID: 41063017.

[89] Harris J, Germain J, McCoy E, Schofield R. Ethical guidance for conducting research with
online communities: A scoping review of existing guidance. PLoS ONE
2024;19(5):e0302924. doi: 10.1371/journal.pone.0302924. PMID: 38758778.

[90] Fairweather D, Beetler DJ, McCabe EJ, Lieberman SM. Mechanisms underlying sex
differences in autoimmunity. Journal of Clinical Investigation 2024;134:e180076. doi:
10.1172/JCI180076. PMID: 39286970.

[91] Coyle PK. What can we learn from sex differences in MS? J Pers Med 2021;11. doi:
10.3390/jpm11101006. PMID: 34683148.

[92] Aldrete JA. Chronic adhesive arachnoiditis. Br J Anaesth 2004;93:301–3. doi:
10.1093/bja/aeh591. PMID: 15251994.

[93] Fagundes W, Zottele MZ, Cavalcanti M, Silva YP. Neurosurgical challenges in recurrent
adhesive arachnoiditis after spinal anesthesia for Cesarean delivery: case report and
literature review. Cureus 2025;17:e86379. doi: 10.7759/CUREUS.86379. PMID: 40688970.

[94] Silva M, Halpern SH. Epidural analgesia for labor: current techniques. Local Reg Anesth
2010;3:143–53. doi: 10.2147/LRA.S10237. PMID: 23144567.

[95] Cesare N, Grant C, Nsoesie EO. Understanding demographic bias and representation in
social media health data. WebSci 2019 - companion of the 11th ACM Conference on Web
Science, Association for Computing Machinery; 2019, p. 7–9. doi:
10.1145/3328413.3328415.

[96] Whitaker C, Stevelink S, Fear N. The use of Facebook in recruiting participants for health
research purposes: a systematic review. J Med Internet Res 2017;19:e290. doi:
10.2196/jmir.7071. PMID: 28851679.

[97] Shumway NK, Cole E, Fernandez KH. Neurocutaneous disease: Neurocutaneous
dysesthesias. J Am Acad Dermatol 2016;74:215–28. doi: 10.1016/j.jaad.2015.04.059.
PMID: 26775772.

[98] Yamada S, Lonser RR, Colohan AR, Yamada CT. Tethered cord syndrome in adult and late-
teenage patients without neural spinal dysraphism. In: Yamada S, editor. Tethered cord
syndrome in children and adults. 2nd ed, Stuttgart: Georg Thieme Verlag KG; 2010, p. 162–
79. doi: 10.1055/b-002-80413.

[99] Phi JH, Lee DY, Jahng TA, Chung CK, Kim HJ. Tethered cord syndrome in adulthood:
reconsidering the prognosis. J Korean Neurosurg Soc 2004;36:114–9.

[100] Oz O, Ulas U, Duz B, Yücel Mehmet, Odabasi Z. Electrophysiological findings in patients
with adult tethered cord syndrome. Turk Neurosurg 2010;20:16–20.

[101] Nogués MA, Stålberg E. Electrodiagnostic findings in syringomyelia. Muscle Nerve
1999;22:1653–9.

[102] Hulens M, Bruyninckx F, Dankaerts W, Vansant G, De Mulder PA. Electromyographic
abnormalities associated with symptomatic sacral Tarlov cysts. Pain Practice
2016;16:E81–8. doi: 10.1111/papr.12441. PMID: 26952047.

[103] Hulens M, Bruyninckx F, Somers A, Stalmans I, Peersman B, Greet V, et al.
Electromyography and a review of the literature provide insights into the role of sacral
perineural cysts in unexplained chronic pelvic, perineal and leg pain syndromes. Int J Phys
Med Rehabil 2017;5. doi: 10.4172/2329-9096.1000407.

[104] Luthra K, Darwish Y, Ritter S, Gopal N, Benkovic S, Suri P, et al. Intercepting Intracept: A
case report of idiopathic arachnoiditis. J Rehab and Pain Med 2023;1:168–75. doi:
10.37191/mapsci-jrpm-1(3)-018.

[105] Cornelson SM, Johnnie ED, Kettner NW. Neural mobilization in a 54-year-old woman with
postoperative spinal adhesive arachnoiditis. J Chiropr Med 2018;17:283–8. doi:
10.1016/J.JCM.2018.07.004. PMID: 30846922.

[106] Ospelnikova TP, Shitova AD, Voskresenskaya ON, Ermilova E V. Neuroinflammation in the
pathogenesis of neuropathic pain syndrome. Neurosci Behav Physiol 2023;53:27–33. doi:
10.1007/S11055-023-01387-8/METRICS.

[107] Yamada S, Won DJ, Pezeshkpour G, Yamada BS, Yamada SM, Siddiqi J, et al.
Pathophysiology of tethered cord syndrome and similar complex disorders. Neurosurg
Focus 2007;23:E6. doi: 10.3171/FOC-07/08/E6. PMID: 17961011.

[108] Shih P, Halpin RJ, Ganju A, Liu JC, Koski TR. Management of recurrent adult tethered cord
syndrome. Neurosurg Focus 2010;29:1–5. doi: 10.3171/2010.3.FOCUS1073. PMID:
20594003.

[109] Hodges PW, Gandevia SC. Changes in intra-abdominal pressure during postural and
respiratory activation of the human diaphragm. J Appl Physiol 2000;89:967–76. doi:
10.1152/JAPPL.2000.89.3.967. PMID: 10956340.

[110] Aktas G, Kollmeier JM, Joseph AA, Merboldt KD, Ludwig HC, Gärtner J, et al. Spinal CSF
flow in response to forced thoracic and abdominal respiration. Fluids Barriers CNS
2019;16. doi: 10.1186/S12987-019-0130-0. PMID: 30947716.

[111] Zhang Z, Wang X, Jonas JB, Wang H, Zhang X, Peng X, et al. Valsalva manoeuver, intra-
ocular pressure, cerebrospinal fluid pressure, optic disc topography: Beijing intracranial
and intra-ocular pressure study. Acta Ophthalmol 2014;92:e475-80. doi:
10.1111/AOS.12263. PMID: 24020862.

[112] Depauw PRAM, Groen RJM, Van Loon J, Peul WC, Malbrain MLNG, De Waele JJ. The
significance of intra-abdominal pressure in neurosurgery and neurological diseases: A
narrative review and a conceptual proposal. Acta Neurochir (Wien) 2019;161:855–64. doi :
10.1007/S00701-019-03868-7. PMID: 30911831.

[113] Lloyd RA, Butler JE, Gandevia SC, Ball IK, Toson B, Stoodley MA, et al. Respiratory
cerebrospinal fluid flow is driven by the thoracic and lumbar spinal pressures. J Physiol
2020;598:5789–805. doi: 10.1113/JP279458. PMID: 32990956.

[114] Heiss JD, Snyder K, Peterson MM, Patronas NJ, Butman JA, Smith RK, et al.
Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine 2012;17:367–80. doi:
10.3171/2012.8.SPINE111059. PMID: 22958075.

[115] Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and
exercise for chronic pain in adults: An overview of Cochrane Reviews. Cochrane Database
Syst Rev 2017;1. doi: 10.1002/14651858.CD011279.PUB2. PMID: 28087891.

[116] Grooten WJA, Boström C, Dedering Å, Halvorsen M, Kuster RP, Nilsson-Wikmar L, et al.
Summarizing the effects of different exercise types in chronic low back pain – a
systematic review of systematic reviews. BMC Musculoskelet Disord 2022;23:49. doi:
10.1186/S12891-022-05722-X/TABLES/21. PMID: 35996124.

[117] Lima L V., Abner TSS, Sluka KA. Does exercise increase or decrease pain? Central
mechanisms underlying these two phenomena. J Physiol 2017;595:4141–50. doi:
10.1113/JP273355. PMID: 28369946.

[118] Leitzelar BN, Koltyn KF. Exercise and neuropathic pain: a general overview of preclinical
and clinical research. Sports Med Open 2021;7. doi: 10.1186/S40798-021-00307-9. PMID:
33751253.

[119] Jackson A, Isherwood I. Does degenerative disease of the lumbar spine cause
arachnoiditis? A magnetic resonance study and review of the literature. British Journal of
Radiology 1994;67:840–7. doi: 10.1259/0007-1285-67-801-840. PMID: 7953223.

[120] Epstein JA, Epstein BS, Lavine LS, Rosenthal AD, Decker RE, Carras R. Obliterative
arachnoiditis complicating lumbar spinal stenosis. J Neurosurg 1978;48:252–8. doi:
10.3171/JNS.1978.48.2.0252. PMID: 624974.

[121] Cancino GG, López-Valdés JC, Valdez-Rodríguez A, Loreto-Lucas M, Vega-Moreno DA,
Betancourt-Quiroz C, et al. Predisposing factors for failed back surgery syndrome
following lumbar instrumentation: retrospective study. Cirugía de Columna 2025;3:253–9.
doi: 10.35366/120969.

[122] Ahn M-W, Kim Y-Y, Byun W-M. The arachnoiditis-like nerve root distribution in the thecal
sac of the degenerative disc diseases. J Korean Soc Spine Surg 1997;4:300–8. doi:
10.4184/jkss.1997.4.2.300.

[123] Klepinowski T, Orbik W, Sagan L. Global incidence of spinal perineural Tarlov's cysts and
their morphological characteristics: a meta-analysis of 13,266 subjects. Surgical and
Radiologic Anatomy 2021;43:855–63. doi: 10.1007/s00276-020-02644-y. PMID:
33452905.

[124] Carroll MB. Hypermobility spectrum disorders: A review. Rheumatol Immunol Res
2023;4:60–8. doi : 10.2478/rir-2023-0010. PMID: 37637226.

[125] Henderson FC, Austin C, Benzel E, Bolognese P, Ellenbogen R, Francomano CA, et al.
Neurological and spinal manifestations of the Ehlers–Danlos syndromes. Am J Med Genet
C Semin Med Genet 2017;175:195–211. doi: 10.1002/AJMG.C.31549. PMID: 28220607.

[126] Fitzcharles MA, Perrot S, Häuser W. Comorbid fibromyalgia: A qualitative review of
prevalence and importance. Eur J Pain 2018;22:1565–76. doi: 10.1002/EJP.1252. PMID:
29802812.

[127] Wawrzyniak A, Lubiatowski P. Shoulder arthropathy secondary to syringomyelia:
systematic review. EFORT Open Rev 2023;8:26–34. doi: 10.1530/EOR-22-0008. PMID:
36705617.

[128] Henke AM, Billington ZJ, Gater DR. Autonomic dysfunction and management after spinal
cord injury: a narrative review. J Pers Med 2022;12. doi: 10.3390/JPM12071110. PMID:
35887607.

[129] Muro K, DiPatri Jr. AJ, McLone DG. The Cervical Tethered Spinal Cord. In: Yamada S, editor.
Tethered Cord Syndrome in Children and Adults. Second, Stuttgart: Georg Thieme Verlag
KG; 2010, p. 102–9. doi: 10.1055/b-002-80413.

[130] Her YF. A proposed multimodal therapy approach for the treatment of arachnoiditis. J Clin
Med Case Stud 2024;9. doi: 10.4172/JClinMedCaseStud.9.2.001.

[131]   Jha S. Algorithms at the gate - radiology's AI adoption dilemma. JAMA 2023;330:1615–6.
1408   doi: 10.1001/jama.2023.16049. PMID: 37801311.

1409   [132]   Bock A, Hswen Y. How artificial intelligence will enhance imaging access and analysis.
1410   JAMA 2024;331:1979–81. doi 10.1001/jama.2024.7251. PMID: 38787567.

1411   [133]   Wangberg SC, Andreassen HK, Prokosch HU, Santana SMV, Sørensen T, Chronaki CE.
1412   Relations between internet use, socio-economic status (SES), social support and
1413   subjective health. Health Promot Int 2008;23:70–7. doi: 10.1093/HEAPRO/DAM039.
1414   PMID: 18083686.

1415   [134]   Hasebrink U, Jensen KB, Bulck H Van Den, Hölig S, Maeseele P. Media audiences
1416 |changing patterns of media use across cultures: a challenge for longitudinal research. Int
1417   J Commun 2015;9:435–57.

1418   [135]   Faye F, Crocione C, Anido de Peña R, Bellagambi S, Escati Peñaloza L, Hunter A, et al.
1419   Time to diagnosis and determinants of diagnostic delays of people living with a rare
1420   disease: results of a Rare Barometer retrospective patient survey. European Journal of
1421   Human Genetics 2024;32:1116–26. doi: 10.1038/s41431-024-01604-z. PMID: 38755315.

1422   [136]   Baxter MF, Hansen M, Gration D, Groza T, Baynam G. Surfacing undiagnosed disease:
1423   consideration, counting and coding. Front Pediatr 2023;11. doi:
1424   10.3389/fped.2023.1283880. PMID: 38027298.

1425   [137]   Ng IK, Tham SZ, Singh GD, Thong C, Teo DB. Medical gaslighting: a new colloquialism.
1426   American Journal of Medicine 2024;137:920–2. doi: 10.1016/j.amjmed.2024.06.022.
1427   PMID: 38936758.

1428   [138]   Shapiro D, Hayburn A. Medical gaslighting as a mechanism for medical trauma: case
1429   studies and analysis. Curr Psychol 2024;43:34747–60. doi: 10.1007/S12144-024-06935-
1430   0/TABLES/1.

1431   [139]   Halverson CME, Penwell HL, Francomano CA. Clinician-associated traumatization from
1432   difficult medical encounters: Results from a qualitative interview study on the Ehlers-
1433   Danlos Syndromes. SSM - Qualitative Research in Health 2023;3:100237. doi:
1434   10.1016/J.SSMQR.2023.100237. PMID: 37426705.

1435   [140]   Rust R, Yin H, Buil BA, Sagare AP, Kisler K. The blood-brain barrier: a help and a hindrance.
1436   Brain 2025. doi: 10.1093/BRAIN/AWAF068. PMID: 39969549.

1437   [141]   Feigenbaum F, Parks SE, Chapple KM. Prospective validation of a quality-of-life measure
1438   for women undergoing surgical intervention for symptomatic sacral Tarlov cysts: the
1439   Tarlov cyst quality of life scale. World Neurosurg 2022;165:e276–81. doi:
1440   10.1016/J.WNEU.2022.06.033. PMID: 35700862.

1441

1442

1443